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ABSTRACT 
A reduction in tobacco use is one of the stated aims of the National Health Promotion 
Strategy (2000-2005) (Department of Health and Children, 2000a) as well being the core 
activity of membership for all health promoting hospitals (HPH). 
AIMS OF THE STUDY 
1. To develop a database of smoking cessation services in Ireland. 
2. Do a census of the smoking cessation services in Ireland and evaluate the range and 
availability of them. 
3. Develop a database for use in smoking cessation treatment services which would schedule 
consultations with patients and gather all relevant demographics, treatments and their 
outcomes, (cessation treatment database) and pilot its use over a 3 month period. 
4. Conduct a patient satisfaction survey of the service users. 
RESEARCH METHODS:   
1. The database of services was compiled from existing information supplemented by 
further enquiry and validation.  It was then used as the population base for a survey of 
services using a specially developed, structured self-administered questionnaire which was 
completed by the smoking cessation service providers identified from the database.  
2. Having developed an “Excel” based smoking cessation treatment database, workshops 
were held around the country and used to further develop and demonstrate it.  At these 
workshops smoking cessation service providers were encouraged to (SPs) into pilot its use 
for a 3 month period.  Data on patients was entered into the database by SPs during the 3 
month pilot and was subsequently analysed. 
3. A patient satisfaction survey was also carried out during this 3 month period using a 
custom built survey instrument with the cooperation of the SPs. 
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FINDINGS:  
1.  A database of 93 smoking cessation service providers was established.  
2.  The subsequent census done found that all SPs had some specific training in smoking 
cessation, more than  2 years’ experience and are employing evidence based interventions. 
3.  Of the 93 SPs identified 49 agreed to take part in the 3 month pilot of the cessation 
treatment database.  Completed treatment databases were received from 41 of the SPs into 
which 1490 patients were entered.  400 patients reported smoking less than 20 per day, 
while 1036 patients reported smoking more than 20 per day.  Higher cigarette consumption 
did not demonstrate any statistically significant difference in quit rates either at 4 weeks 
(37%) or at 3 months (22.4%). Socio-economic (SE) groups 1-3 demonstrated quit rates of 
41% at 4 weeks and 28% at 3 months while SE groups 4-6 demonstrated quit rates of 39% 
at 4 weeks and 23% at 3 months making social class statistically associated with quit rates. 
Patient status ( whether treated as an in-patient/out-patient or in the community) was 
statistically significant at 4 weeks (P < 0.05) but not at 3 months in the case of inpatients 
the quit rate fell from 40% at 4 weeks to 24% at 3 months. 
4.  A total of 342 patient satisfaction questionnaires were received and these demonstrated 
that less than 7% of the patients had to wait for more than 4 weeks for an appointment and 
almost all (94%) were satisfied and would be happy to return to the service. 
 
CONCLUSIONS:  
Database of cessation service providers 
No up to date comprehensive database of service providers existed and there was no 
circulation to health professionals of contacts to aid referrals. 
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Census of smoking cessation services 
There is a need for services in psychiatric settings, for standardised follow up of patients 
and training 61% identified need for further training.  There was poor data collection, 32% 
of SPs do not have access to a PC and poor use is being made of the data they do collect. 
Treatment Database 
Quit rates of 37% at 4 weeks and 22.4% at 3 months of all those entered into the database. 
There were low quit rates in pregnant women at 16.5% and consistently poor outcomes in 
vulnerable populations.  There were low referrals from outside cessation services. 
Patient Satisfaction Questionnaire 
Patients preferred time of appointment was weekday mornings.  Prescription cost did not 
deter their participation in the treatment programme.  94% Patients were very happy with 
service and would be happy to return. 
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CHAPTER 1  BACKGROUND ON TOBACCO AND SMOKING CESSATION 
 
1.1 Background 
Tobacco use is a major preventable cause of death and chronic disability in Ireland today 
and a major cause of health inequality.  Tobacco use is a major killer: in Ireland between 
the years of 1950 – 2000 approximately 235,000 were attributed to it.  Half of them died in 
middle age (35-69yrs) and many of those killed in middle age would have lived on for 10, 
20, 30 or more good years.  About 22 years of life are lost, by those killed in middle age by 
smoking (2006 www.deathsfromsmoking.net). 
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The strategic aim of the National Health Promotion Strategy 2000/2005 was to increase the 
percentage of the population who remain non-smokers with a particular emphasis on 
narrowing the gap across social classes and to protect non-smokers from passive smoke.  Its 
objectives were to develop, implement and evaluate models of best practice in smoking 
cessation for lower socio-economic groups (Department of Health and Children, 2000).  
The review of the National Health Promotion Strategy 2004, noted that additional work was 
needed to develop and disseminate national guidelines for smoking cessation training 
(Department of Health Promotion et al., 2004). 
 
Early development of smoking cessation services in Ireland occurred within the acute 
hospital sector, as part of HPH membership with little funding. Momentum was gained 
following the publication of the National Cardiovascular Strategy.  This strategy called for 
the provision and access to smoking cessation services countrywide and allocated funding 
for this development (Department of Health and Children, 1999).  Unfortunately this 
development was never fully realised.  In 2003, further impetus was gained when the 
availability of smoking cessation services countrywide was seen as a key national strategy 
developed in conjunction with the introduction of the 2004 smoking ban in Ireland. 
 
Smoking prevalence has been decreasing since the 1980’s.  The most up to date national 
rate is 24% (OTC et al., 2010), but the rate of decrease has been slowing since the mid-
1990s.  However, rates of tobacco use are increasing in young women and in people from 
lower socio-economic groups (Kelleher et al., 2003) (Layte and Whelan, 2004). 
20 
 
Environmental tobacco smoke has also been linked with lung cancer in non-smokers 
(Hackshaw et al., 1997).  The use of tobacco during pregnancy is one of the most important 
risk factors for neonatal and late foetal deaths (Doll et al., 1994).    
 
Smoking rates among women are increasing whereas among young men they are 
decreasing (HBSC 2001/02).  The 1998 European Community Household Panel (ECHP) 
survey found that young Irish women (aged 16-24) had prevalence rates of 35% (2nd 
highest of the 11 countries) for those with “low” educational attainment compared to 24% 
for those with “high” educational attainment (Commission and Group, 1998). The 2000 
ECHP found that there have actually been increases in smoking among lower income and 
lower social class groups. Smoking among manual working class groups are twice those of 
professional and managerial groups (Europen Commission and Group, 2000).  The fact that 
many studies show that smoking is more prevalent in the lower socio-economic groups 
suggests that these are the groups that tobacco control policies should especially focus on. 
Tobacco is a highly addictive substance and the difficulties associated with quitting are 
well documented. In 1988 a report by the US Surgeon General identified cigarette smoking 
as nicotine addiction (General, 1988).  Cigarette smoking is a chronic relapsing disease and 
has been classified as a mental and behavioural disorder according to the WHO 
International Classification of Diseases, lCD-l0 (F17.228). The most important component 
of daily smoking is nicotine dependence and most people need to attempt quitting several 
times before they are successful (WHO, 1997). Smoking cessation services are an 
invaluable resource for smokers who wish to quit, as it is very difficult to stop smoking 
without help and about 90% who try will be smoking again 6 months later (Bandolier, 
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2008). Smoking cessation services can help smokers to quit their smoking habit which in 
turn will help to reduce smoking prevalence.  This will lead to the improvement of health 
status; reduce morbidity, and premature mortality in the population.  Disease risks are 
reduced following smoking cessation and those smokers who stop before middle age can 
avoid most of the excess risk they would have suffered (Doll et al., 1994). Cessation of 
smoking at any age is associated with risk reduction.  Helping smokers stop can be 
provided in different ways through brief interventions, behavioural therapy, self-help 
materials, and pharmacotherapies.  There is evidence that these are effective and improve 
long term quit rates (Hughes et al., 2004).  Most smokers want to stop but their chances of 
success are low unless they are offered support and treatment. Brief advice, 
pharmacotherapies and more intensive behavioural support have all been shown to increase 
a smoker’s chance of stopping (Raw et al., 1999). 
 
In 2001, the World Health Organisation highlighted that the provision of smoking cessation 
services for adults could bring about quicker health gains than a complete focus on 
preventing people from starting to smoke.  Tobacco continues to kill nearly 6 million 
people each year, including more than 600,000 non-smokers who die from exposure to 
tobacco smoke.  Up to half of the world’s 1 billion smokers will eventually die of a 
tobacco-related disease (WHO, 2011). 
Total tobacco-attributable deaths are projected to rise from 5.4 million in 2005 to 6.4 
million in 2015 and 8.3 million in 2030 (Mathers and Loncar, 2006), unless more effective 
measures are introduced to help smokers to stop smoking or at least reduce their tobacco 
consumption.  
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The Warsaw Declaration for a Tobacco-Free Europe, 19 February 2002, acknowledged that 
tobacco is a toxic and addictive substance and that the tobacco epidemic is one of the 
greatest public health challenges facing the World Health Organisation’s (WHO) European 
region. It was also emphasized that smoking cessation strongly contributes to a decrease in 
smoking prevalence (WHO, 2002).  It is clear from previous Cochrane reviews that both 
simple advice and nicotine replacement therapy can improve the chances of quitting in 
some patients (Silagy et al., 2004) (Lancaster and Stead, 2004) and should form  part of a 
primary care strategy for smoking cessation. 
Behavioural strategies to aid smoking cessation range from very brief interventions, such as 
advice from a physician, to intensive multi-component programmes. There is good 
evidence for the effectiveness of brief, therapist-delivered interventions, such as physician 
advice (Lancaster and Stead, 2004), and for the additional effect of more intensive 
behavioural interventions, such as group therapy, (Stead and Lancaster, 2005) individual 
counselling (Lancaster and Stead, 2005) and telephone counselling (Stead et al., 2003).  
Most successful quitters give up on their own (Hatziandreu et al., 1990).  Existing evidence 
was summarised for both the older and newer forms of self-help interventions in promoting 
smoking cessation and found that providing smokers with materials to support quit attempts 
is of limited benefit unless the materials take into account each smoker's individual 
characteristics (Lancaster and Stead 2005). 
   
It was found that training health professionals to provide smoking cessation interventions 
(to ask people if they smoke and offering them advice) had a measurable effect on 
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professional performance (trained persons were more likely to perform tasks of smoking 
cessation than untrained controls) but did not find strong evidence that it changed smoking 
behaviour (Lancaster et al., 2000). Having smoking cessation programmes in pregnancy 
was found to reduce the proportion of women that continue to smoke, and reduce low birth 
weight and preterm birth (Lumley et al., 2009).  Advice and support from nurses may help 
people to stop smoking, especially when they are in hospital (Rice and Stead, 2004).  High 
intensity behavioural interventions that include at least one month of follow-up contact are 
effective in promoting smoking cessation in hospitalised patients (Rigotti et al., 2007).  
Smoking related mortality is likely to rise substantially unless effective interventions are 
put in place to reduce smoking prevalence (Ezzati and Lopez, 2003). Unfortunately, 
training of health professionals in smoking cessation services is inadequate in Europe 
(Kabir et al., 2011). 
Smoking cessation interventions are effective both in terms of cost and outcome.  Research 
evidence shows that there are highly cost-effective ways to help people stop smoking 
(Christenhusz et al., 2011). The potential savings to the drugs bill if more smokers stop is 
considerable. Quitting smoking can eliminate the need for cholesterol-lowering medication 
(statins) and result in significant cost savings (Nicklas et al., 1999).  Smoking cessation 
interventions are about 17 times more cost effective than statins  (McNeill A, 2000). 
 
1.2  Development of cessation services in Ireland 
 
Through the ‘Europe against Cancer’ programme failed to achieve its target of reducing 
cancer deaths by 15% by the year 2000 and as a result of this failure the European 
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Community has set as one of its objectives reducing the number of cases of cancer and 
other diseases related to smoking by stating that renewed tobacco control efforts are needed 
along with increased screening. 
 
The EU Council recommendations on prevention of smoking and on initiatives to improve 
tobacco control, 2002, recommends that member states continue developing strategies and 
measures to reduce the prevalence of smoking, such as general programmes to overcome 
tobacco addiction.  Article 14 of the Framework Convention on Tobacco Control (FCTC) 
requires Parties to “include diagnosis and treatment of tobacco dependence and counselling 
services on cessation of tobacco use, in national health and education programmes, plans 
and strategies” and to “develop and disseminate appropriate, comprehensive and integrated 
guidelines” in order to take “effective measures to promote cessation of tobacco use and 
adequate treatment for tobacco dependence”.  
By ratifying the WHO Framework Convention on Tobacco Control (FCTC), Ireland has 
agreed to develop and disseminate appropriate, comprehensive and integrated guidelines 
based on scientific evidence and best practices and to take effective measures to promote 
cessation of tobacco use and adequate treatment for tobacco dependence.  In addition 
Ireland has agreed to design and implement effective programmes aimed at promoting the 
cessation of tobacco use. 
 
In June 2001 the WHO Tobacco Free initiative developed policy recommendations for 
smoking cessation and treatment of tobacco dependence.  These were published in June 
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2003 and launched during the 12th World Conference on Tobacco or Health in Helsinki, 
Finland.  The recommended framework includes a mix of three main strategies: 
(WHO, 2003a). 
1. A public health approach that seeks to change the social climate and promote a 
supportive environment;  
2. A health systems approach that focuses on promoting and integrating clinical best 
practices (behavioural and pharmacological) which help tobacco-dependent consumers 
increase their chance of quitting successfully.  
3. A surveillance, research and information approach that promotes the exchange of 
information and knowledge so as to increase awareness of the need to change social norms. 
 
In Ireland ‘Towards a Tobacco Free Society’, a report of the Tobacco Free Policy Review 
Group  has as one of its key targets to significantly increase the number of people who stop 
smoking each year and to systematically evaluate services provided with a view to 
promoting best practice (Department of Health and Children, 2000b). 
A key method of achieving this target is the provision of cessation programmes to assist 
smokers to quit. The Minister for Health and Children launched the National Smoking 
Cessation campaign, ‘Every Cigarette is Doing You Damage’ in November 2003 and the 
Health Service Executive (HSE) recently launched a campaign in June 2011’You can Quit’. 
Smoking cessation services are available free of charge throughout Ireland and are provided 
in both community and hospital settings. Different types of services exist and are provided 
by health care professionals from different disciplines and community workers.  
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Key objectives of Ireland’s National Health Strategy “Quality and Fairness: A Health 
System for You” (Department of Health and Children, 2001)  included intensifying the 
promotion of health and well-being,  reducing health inequalities and developing evidence 
and strategic objectives to underpin all planning and decision-making. It also stated that a 
reduction in smoking will continue to be targeted through Government fiscal policies. 
 
The National Health Information Strategy advocates the establishment of processes that 
ensure the fuller use of health information in policy making, service planning, 
implementation processes, and health information standards that ensure the quality and 
comparability of health information. It points out that information is needed on the 
effectiveness of health promotion, protection and intervention initiatives (Department of 
Health Promotion et al., 2004). 
 
The National Cancer, Cardiovascular and Health Promotion Strategies and the report of the 
Task Force on Sudden Cardiac Death (2006), emphasise the importance of reducing the 
prevalence of smoking in order to improve health status and reduce premature mortality 
(DOHC, 2006). 
 
1.3 Smoking cessation  
 
At any given time four out of five smokers would like to quit smoking. Two thirds of 
smokers have tried quitting at some stage. For those who quit unaided there is less than a 
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5% chance of being abstinent after one year (WHO, 1997).  Smokers go through a quitting 
process which may include some or all of the following: 
 thinking about quitting,  
 planning to quit,  
 attempting to quit,  
 remaining abstinent,  
 going back to smoking.  
 
This cycle may be repeated many times. Smoking cessation intervention and treatment aids 
have been shown to significantly increase the number of successful quit attempts. Cessation 
programmes can provide either psychological and behavioural support and or provision of 
pharmacological aids. Such programmes can be administered through a variety of primary, 
secondary, and community care facilities.  
 
Tobacco control legislation enables the government to implement and direct policies, set 
tobacco prices and taxes, ban advertisement and sponsorship, and instigate mass public 
education campaigns. 
 
It was known that while services are available in all of the four Health Service Executive 
(HSE) regions, it would appear that there is little uniformity or consistency countrywide in 
the delivery of these services. In some regions, single services are expected to effectively 
cover extremely large geographical areas while others are limited to very small community 
based areas or to single hospital catchment areas.  While full-time dedicated staff are 
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available to provide services in some regions, in other regions the service is provided on a 
part-time or voluntary basis only. In many cases, services appear to be very limited and 
patchy and access is focused towards specific population groups, for example, cardiac or 
respiratory patients.  
 
The Irish Health Promoting Hospital Network (IHPH) managers of smoking cessation 
services as well as the service providers themselves had previously suggested that there is 
no systematic follow up, and current review and evaluation is dependent on local resources. 
At present there is no national structure in place to assist in this process and consequently 
no collation of local findings that could assist with an adequate review on the value and 
effectiveness of current smoking cessation services. This information is crucial if Irish 
health service planners are to have the necessary information that can ensure the integration 
of cessation services into an improved quality healthcare, one that can adequately respond 
to the challenge of reducing tobacco use which is already known as the single most 
important public policy action that will bring about significant health gains.       
 
Since the development of the Health Promoting Hospital (HPH)-Smoke Free Hospital 
Initiative in 1999 dialogue and discussion has taken place around the issue and 
developmental needs of smoking cessation services, primarily those within the hospital 
setting.   
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HPH Coordinators and Smoking Cessation Facilitators meet regularly to share and make 
recommendations. Since 2002, the need for standardised guidelines for cessation services 
was identified, as was the need for a national data collection system. 
In 2005, HPH Smoking Cessation facilitators identified the fact that there was no central 
data collection and storage system, which could help in evaluation of the service with a 
view to further development and identification of needs of the service. 
A number of discussions took place between the Director General of TFRI and the Director 
of the HPH Network prior to development of a proposal where it was hoped to address 
these issues.  Subsequently meetings took place with the TFRI team and staff involved in 
smoking cessation and health promotion. 
To date in Ireland there has been no comprehensive national study of the availability, 
appropriateness or effectiveness of smoking cessation services. Smoking cessation services 
are available throughout Ireland.  Different types of services exist, delivered by health care 
professionals and community workers. 
 
The research planned in this programme will make a significant contribution in improving 
our understanding of the way smoking cessation services are delivered nationally.   
 
The data generated by this research will enhance evidence based policy which will inform 
the provision of smoking cessation services in Ireland. Improved planning and delivery of 
these services will result through identification of standards based on international best 
practice and the identification of inequalities in service provision.  This is in keeping with 
one of the objectives of our Health Strategy “Quality and Fairness” which advocates an 
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evidence based approach - National Goal No 4 ‘High Performance’ ( Department of Health 
and Children, 2001).  
Chapter 2 outlines the health effects of smoking tobacco and the reasons behind the 
government’s plan to significantly increase the numbers who stop smoking each year and to 
systematically evaluate services provided. 
 
Chapter 3 outlines treatment of nicotine addiction/dependence, different pharmacological 
treatments available to aid sufferers quit their addiction as well as the different type of 
treatment programmes provided.  In this chapter I will also discuss typically expected 
success rates from treatment programmes and how these rates are validated. 
 
Chapter 4 outlines the study methodology of this project. 
 
Chapter 5 presents results of the cessation service database, the census of cessation service 
provider’s questionnaire, results of the 3 month pilot use of the treatment data collection 
instrument and the patient satisfaction questionnaire. 
 
Chapter 6 discusses the project results. 
 
Chapter 7 discusses study limitations and conclusions of the project. 
 
Chapter 8 shows future recommendations. 
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CHAPTER 2   HEALTH EFFECTS OF SMOKING TOBACCO AND 
GOVERNMENT STRATEGY TO INCREASE NUMBERS WHO QUIT ANNUALLY 
 
2.1 Adverse health effects, diseases and deaths caused by tobacco smoke 
In 1964 the first Surgeon General’s report on the adverse health effects from smoking was 
published.  Since then for over 50 years there have been thousands of studies supporting 
these adverse effects.  Tobacco use remains the single most preventable cause of death for 
both men and women in America (Surgeon General, 2010). 
The surgeon general’s report states that having looked at the evidence on the mechanisms 
by which smoking causes disease that there is no risk free level of exposure to tobacco 
smoke (Surgeon General, 2010). 
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The WHO estimates that half of the world’s children (700 million) are exposed to SHS. 
Children are especially vulnerable to the effects of SHS as they breathe more rapidly and 
they inhale more pollutants per pound of body weight than adults. A child exposed to SHS 
has an increased risk of asthma, lower respiratory infections, bronchitis, middle ear disease, 
bacterial meningitis and SIDS as well as generally reduced respiratory function (cough, 
wheezes). Children are more likely to smoke if their parents are smokers.  In Ireland 29% 
of adults still smoke totalling to almost 1 million smokers (Kabir et al., 2011).    If w our 
smoking cessation rates were improved not only would this reduce the burden of disease on 
the state it would also protect from exposure to secondhand smoke as well as preventing 
some children from initiating smoking.  Reducing the number of smokers in the county is 
paramount to the health of the nation and in reducing the number of smokers would also 
improve the health of our children.   For example 14.8% (13.9% in young males, 15.4% in 
young females) of Irish children aged 13-14yrs old were exposed to second hand smoke in 
cars (Kabir et al., 2009).  If there were fewer smokers this would lead to a reduction of 
exposure to second-hand smoke to children in all areas including confined and enclosed 
spaces such as cars. 
 
Chronic diseases which result from active and passive smoking impose an enormous 
burden on our health care system.  Figure 2.1 shows the leading causes of death worldwide 
as well as showing how many millions of them are related to tobacco use in 2005.  A cost-
effective comprehensive tobacco dependence treatment program can accelerate further 
declines in smoking rates (Currie et al., 2012). 
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Figure 2.1 Tobacco use is a risk factor for six of the eight leading 
causes of death in the world 
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Hatched areas in  figure 2.1 indicate proportions of deaths which are as a result of tobacco 
use, * includes mouth oropharyangeal cancer, oesophageal cancer, stomach cancer, liver 
cancer, other cancers as well as cardiovascular diseases other than ischaemic heart disease 
and cerebrovascular disease (WHO, 2008). 
Tobacco use is the leading preventable cause of death in the world and was responsible for 
over 5 million deaths worldwide in 2005, mostly in poor countries and among the poorer 
populations.  The number of deaths as a result of tobacco is likely to rise to 10 million by 
2023 unless measures known and proven to reduce tobacco use are implemented (WHO, 
2003b).  655,000 people die every year in the EU as a consequence of tobacco related 
diseases  (Peto et al., 1992). 
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There is a 2-fold increase in death rate in middle-age of smokers (35-69) compared to non-
smokers (Doll et al., 2004). 
Smoking is a strong risk factor for six of the eight leading causes of death around the world, 
(see figure 2.1) which include: 
 Lower respiratory infections 
 Tuberculosis 
 Trachea, bronchus and lung cancers 
 Chronic obstructive pulmonary disease (COPD) 
 Ischaemic heart disease;  
 Cerebrovascular disease (WHO, 2008) 
 
 
 
Figure 2.2 Diseases caused by smoking 
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(WHO, 2011) 
 
2.2 Tobacco and cancer  
 
The global burden of cancer is escalating as a result of the dramatic increases in the use of 
tobacco in the developing world. The use of tobacco is linked to many cancers mainly lung 
cancer which is the single most common cancer in the world. The use of tobacco is 
attributable to 87% of all lung cancer deaths.  There is a dose response relationship between 
cancer risk and tobacco use.  A lifelong smoker is 20 – 30 times more likely to get cancer 
than a non-smoker (Oppeltz and Jatoi, 2011). 
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In 2004, the International Agency for Research on Cancer (IARC) judged that there was 
sufficient evidence in humans that tobacco smoking causes cancers of the lung, larynx, oral 
cavity and pharynx, paranasal sinuses, oesophagus, stomach, pancreas, liver, kidney, ureter, 
bladder, uterine cervix and bone marrow and this list was recently updated to include 
cancer of the colon and rectum (Parkin, 2011a).  It is also responsible for other circulatory 
diseases, stomach and duodenal ulcers, erectile dysfunction and infertility, osteoporosis, 
cataracts, age-related macular degeneration and periodontitis.  
Women who smoke during pregnancy have a substantially higher risk of spontaneous 
abortion (miscarriage) than those who do not smoke. Smoking can also cause complications 
in pregnancy and labour. Babies of smokers are 200 to 250gms lighter than their 
counterparts and more than 25% of sudden infant deaths are attributable to smoking (NICE, 
2008). 
The risk of lung cancer relates to the cumulative exposure to tobacco smoke (duration and 
dose), including the time since quitting in ex-smokers (Parkin, 2011b). 
 
2.3 Tobacco and heart disease 
 
Cigarette smoking is a well-known risk factor for cardiovascular disease both in terms of 
morbidity and mortality (Doll et al., 2004, Freund et al., 1993).  A study from 2012 
concluded that those who smoke more intensely and have a history of a higher number of 
pack years (pack years: the number of cigarettes a person has smoked over time. One pack 
year is defined as 20 manufactured cigarettes (one pack) smoked per day for one year) 
have a lower exercise tolerance and heart rate reserve with a blunted heart rate response to 
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exercise.  They also concluded that after 3 years, physiological treadmill stress testing 
improvement, suggestive of improved Cardio Vascular disease prognosis were observed 
among successful abstainers (Asthana et al., 2012).  There is a nonlinear dose response 
between exposure to tobacco smoke and cardiovascular risk, with a sharp increase at low 
levels of exposure (including exposures from second hand smoke or infrequent cigarette 
smoking) and a shallower dose-response relationship as the number of cigarettes smoked 
per day increases (Surgeon General, 2010).  
 
2.4 Tobacco and respiratory diseases 
 
The two main lung diseases caused by smoking and exposure to Second Hand Smoke 
(SHS) are Chronic Obstructive Pulmonary Disease (COPD) and lung cancer. 50% of 
smokers will develop COPD, Smoking is responsible for 80% of COPD cases (2004).  72% 
of male COPD deaths and 50% of female COPD deaths in Europe in 2000 were due to 
smoking (Scanlon et al., 2000) and there is a two fold increase in the rate of lung function 
decline in smokers compared to sustained (5 years) quitters (Peto et al., 1996). 
Lung cancer is the biggest killer of all the cancer groups, accounting for about 20% of all 
cancer deaths, and cigarette smoking is estimated to be responsible for approximately 90% 
of lung cancer cases.   About 70% of the tar contained in the smoke ends up coating the 
lungs. An average smoker’s lung collects about a mug full of tar each year. When it 
condenses the tar forms a sticky brown substance. Tar contains many cancer causing 
chemicals as well as irritants that causes smokers to cough. 
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2.4.1 Smoking related respiratory diseases in Ireland 
 
Respiratory disease is one of the biggest health burdens, it remains the most common 
reason for a GP visit in Ireland and the third most common reason for hospital admission in 
Ireland and deaths from respiratory disease now exceed those from coronary disease. 
Ireland has the highest death rates from respiratory disease in Europe it being almost twice 
the European average. 
Mortality by type for Respiratory disease in Ireland: 
 Pneumonia   33% 
 Respiratory cancer*  28% 
 COPD    22% 
 Other lung diseases   17% 
E.g. Asthma and pneumoconiosis 
*Includes cancer of nasal cavities, pleura, larynx, trachea, bronchus and lung (Brennan et 
al., 2008). 
Respiratory symptoms are also one of the more commonly reported effects from exposure 
to second hand smoke.  In a study carried out in Ireland in 1995 they found that 46.3% of 
non-smoking children were exposed to smoking in the home with parental smoking 
accounting for most of the passive smoking. In this same study they looked at symptoms in 
both smoking and non-smoking teenagers and found that bronchitis symptoms were more 
commonly reported in active smokers compared to non-smokers with an odds ratio of 3.02 
(95% CI 2.34-3.88) (p < 0.0001) or in passive smokers compared to those not exposed to 
smoking with odds ratio of 1.82 (95% CI 1.32-2.52) (p < 0.0001). This was repeated in 
1998 showing similar results thus documenting that increased bronchitis symptoms occur in 
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teenagers exposed to active or passive smoking (Manning et al., 2002).   Studies also show 
that bar workers experience far fewer respiratory and irritant symptoms following the 
introduction of the smoke-free laws (Goodman et al., 2009). 
 
2.5 Smoking related deaths 
More than 6 million people die every year from tobacco use and exposure to tobacco smoke 
(one death every six seconds) and this is expected to rise over the next 20 years (Figure 
2.3).  There is a two fold increase in death rate in middle-age smokers (35-69) compared to 
non-smokers (Doll et al., 2004). 
Figure 2.3  Cumulative tobacco deaths between 2005 and 2030 
 
(WHO, 2008) 
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It is known from Brennan et al that smoking related diseases are also the most common 
causes of death in Ireland (fig 2.4). 
Figure 2.4   Death by Cause in Ireland in 2004 
(Brennan et al., 2008)  
 
2.6 Principles of tobacco control 
 
Several strategies have been shown to reduce tobacco use but 50 years after the adverse 
health effects of tobacco smoke were proven few countries have established and 
implemented effective strategies to control its use.   
By ratifying the WHO FCTC, 176 countries including Ireland have committed to protecting 
the health of their populations by joining the fight against the tobacco epidemic and the 
WHO has produced the MPOWER strategy package to aid this important task.  
M Monitor tobacco use and prevention policies 
P  Protect people from tobacco smoke 
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O  Offer help to quit tobacco use 
W  Warn about the dangers of tobacco 
E  Enforce bans on advertising, promotion and sponsorship 
R Raise taxes on tobacco products 
Monitoring- Monitoring is essential to provide baseline data which will enable targeting of 
activities, tracking of progress and effectiveness of implementations of policies. Countries 
best at monitoring prevalence of tobacco use can be seen in figure 2.5 and the monitoring 
of tobacco use and tobacco control policies is critical to the success of the other 5 
MPOWER measures. 
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Figure 2.5  Prevalence of Tobacco use worldwide. 
 
 
(WHO, 2011) 
The countries coloured in orange represent those that best monitor the prevalence of 
tobacco use. 
Protection - Smokefree legislation should be in place and be fully enforced to enable totally 
smokefree environments in health care and educational settings, and all indoor workplaces 
including restaurants and bars. Exposure to second hand smoke is responsible for many 
diseases including heart disease, lung cancer, and respiratory diseases.  There is no known 
safe level of exposure to second hand smoke. 
Offer help to quit/cessation - Unless current smokers quit, tobacco deaths will rise 
dramatically in the next 50 years.  Health care systems should be strengthened to enable 
easy availability of tobacco cessation advice and treatment to patients. Quit lines and other 
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community initiatives should be supported along with low cost pharmacological therapy for 
the treatment of tobacco dependence.  
 
Warn - This involves implementation of health warnings on tobacco products and the 
development of counter tobacco advertising. Plain packaging and graphic warnings on 
tobacco products are needed to reduce the attractiveness of tobacco to children. 
 
Enforce - Enforce legislation that comprehensively prevents any form of tobacco 
advertising, promotion and sponsorship both direct and indirect such as product placement. 
 
Raise - Price and Taxation - Increasing price and taxation will help smokers to quit 
smoking, reduce the number of new smokers and thus reduce the number of people exposed 
to secondhand smoke. Significant increases in tobacco taxes are a highly effective tobacco 
control strategy and lead to significant improvements in public health. The positive health 
impact is even greater when some of the revenues generated by tobacco tax increases are 
used to support tobacco control, health promotion and/or other health-related activities and 
programmes (Chaloupka et al., 2012). 
Higher taxes increase government revenues. Contrary to tobacco industry propaganda, 
tobacco tax increases do not decrease government revenues. Increasing tobacco taxes by 
10% generally decreases tobacco consumption by 4% in high-income countries and by 
about 8% in low- and middle-income countries (WHO, 2008).  SimSmoke (SS) which is a 
simulation model used to examine the effects of tobacco control policies on smoking 
prevalence through, initiation, smoking cessation and associated future premature deaths.  
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An adapted model IrelandSS was used recently in study of Irish data from 1998 and 
projected to 2040.  Using this, Ireland SS demonstrated that the result of the policies 
implemented between 1998 through 2010, showed that 1716 fewer smoking attributable 
deaths (SADs) are estimated by 2010 which is reasonably close to results from surveys 
carried out. By 2040, the relative reduction in prevalence increases to 29%, with 50 215 
fewer SADs.  It also showed a 21.8% reduction in prevalence of male smokers from 1998 
to 2010 of which only 9% were attributable to smoking cessation services. Whereas 45% 
was  attributable to price increase (Currie et al., 2012). 
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CHAPTER 3  TREATMENT OF NICOTINE ADDICTION AND THEIR 
EXPECTED OUTCOMES 
 
3.1 Nicotine and Addiction 
 
The chemistry and physiology of nicotine is well known and the addictive nature of the 
drug has been well established.  Absorption of cigarette smoke from the lung is very rapid, 
after every inhalation a high concentration arterial bolus of nicotine is produced and this 
reaches the brain within 10 – 16 seconds, which is faster than by intravenous injection.  
Nicotine has a distributional half-life of 15 – 20 minutes and a terminal half-life in blood of 
two hours.  Therefore smokers experience a pattern of repetitive and transient high levels of 
nicotine from each cigarette smoked which necessitates hourly smoking of cigarettes to 
maintain raised concentrations.  Overnight blood nicotine levels drop close to those of non-
smokers (Jarvis, 2004). 
 
Since the 1980’s it has been accepted that tobacco products are among the most addictive 
and deadly of all dependence producing substances (London, 2000).  Nicotine is carried by 
tar particles to the lung alveoli and then to the brain- a process that takes about 10 seconds 
per inhalation (Russel et al., 1976).  Nicotine binds to nicotine cholinergic receptors in the 
brain which leads to the release of neurotransmitters (Benowitz, 2010,). 
Nicotine has pervasive effects on brain neurochemistry.  It binds to and activates the α4β2 
nicotinic acetylcholine receptor stimulating release of dopamine in the nucleus accumbens, 
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(Fig 3.1) this results in the satisfaction associated with smoking.  A drop in nicotine levels 
leads to craving and withdrawal (Jarvis, 2004). 
Figure 3.1  Effect of nicotine on the brain 
 
 (Tomkins DM and Sellers EM, 2001) 
 
Tobacco addiction is associated with an emotional as well as a physical dependence. It is a 
complex process and to understand its complexity it is important to note the 3 important 
factors that play a part in this addiction: The physical addiction to the drug nicotine, the 
habit which includes handling, the ritual of opening the pack, lighting up, the sound of the 
paper etc. and the psychological / emotional dependence often used as an aid to damp down 
and or control negative feelings of anxiety, frustration or anger. 
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Therefore, the ideal treatment for tobacco-cessation involves a comprehensive approach 
that addresses all major issues of tobacco addiction both pharmacological and non-
pharmacological. 
 
Treatment populations for smoking cessation: 
 
The target population for treatment should be everyone who smokes or uses any tobacco 
product.  Smoking cessations services should aim to treat 5% of population who smoke or 
use other forms of tobacco.  They should aim for a quit rate of 35% at 4 weeks and this quit 
rate should be validated by carbon monoxide monitoring (NICE, 2008). 
 
3.2 Brief intervention  
 
Brief interventions involve opportunistic advice, discussion, negotiation or encouragement. 
They are commonly used in many areas of health promotion and are delivered by a range of 
primary and community care professionals.  Brief intervention with regard to smoking 
takes between 5 and 10 minutes and may include the following: 
 simple opportunistic advice to stop  
 an assessment of the patient’s commitment to quit  
 an offer of pharmacotherapy and/or behavioural support/referral  
(National Institute for Health and Clinical Excellence, 2006) 
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When you compare quit attempts which have been unassisted, to quit attempts following a 
brief intervention, there is a difference in the cessation rate of about 2.5% between those 
who received advice from a physician and those who did not (Lancaster and Stead, 2008). 
 
3.3 Motivational interviewing 
 
The definition of motivational interviewing has evolved over time. Initially it was described 
by William R Miller in 1983 as an approach to behaviour change.  Motivational 
Interviewing has been established as evidence based practice in the treatment of patients 
with substance use disorders. It does not impose change but supports change which fits in 
with the patient’s own beliefs, values and concerns. 
A meta-analysis of 14 randomised trials showed that, as compared with brief advice or 
usual care, motivational interviewing increased 6 month cessation rates by about 30%.  
Cessation rates were higher if smokers received two or more sessions rather than one 
session and if the sessions lasted more than 20 minutes (Hettima et al., 2005). 
 
3.4 Intensive smoking cessation programmes  
Group therapy offers individuals the opportunity to learn behavioural techniques for 
smoking ‘group therapies’ have been described in the literature, most of which come from 
four basic types of approaches:  
Analytical: Its goal is to uncover and resolve hypothetical, unconscious conflicts 
which are expected to lead to the patients’ recovery, i.e. attention to group members’ 
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hidden motivation, interactions and attention to group members’ interactions with group 
leaders. 
Interpersonal: Social learning and feedback i.e. allowing group members learn 
how their behaviour affects others. 
Experimental: This is done mainly by working with the patients’ current awareness 
of their experiences.  The therapists using this approach are encouraged to use techniques 
aimed at stimulating desirable group experiences. 
Didactic: Usually connected primarily with behavioural and cognitive treatments.  
Here the therapists usually have a set agenda for each group session, and the groups are 
given tasks at each meeting. 
More information on different approaches to group treatment, descriptions of group 
processes and of practical skills involved in running groups can be found in Yalom and 
Leszez (2005) and Aveline and Dryden (1988). 
 
3.5 Pharmacological treatments  
Nicotine Replacement Therapies (NRT) 
 
Patches:  Patches deliver a continuous even dose of nicotine over long periods of time and 
there are many different doses and types of patches to choose from. You apply them to the 
upper arm, hip, back or chest, the area chosen should be clean, dry and free of hair before 
applying the patch, to ensure that it sticks. It is also recommended that the site of placement 
of the patch be rotated to avoid any localised skin irritation. Patches should not be placed 
on broken skin and patients are advised not to smoke while wearing a patch. 
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NiQuitin Patches are either opaque in colour or completely clear which allows for more 
discrete use. They come in 3 different strengths 21mg, 14mg and 7mg and are delivered 
over a 24hr period regardless of strength.  NiQuitin suggest the following treatment plan 
when using their product: 
• For 6 weeks, start with the Step 1 (21mg) NiQuitin Patch if you smoke 10 or more 
cigarettes a day. (Go straight to Step 2 (14mg) if you smoke less). 
• For a further 2 weeks, change to the Step 2 (14mg) NiQuitin Patch. (Alternatively 
start with Step 2 (14mg) for 6 weeks if you are a light smoker). 
• Finally, move onto the Step 3 (7mg) NiQuitin Patch for 2 weeks. 
 
Nicorette Patches; Invisipatch is a semi-transparent 25mgs patch and delivers the dose 
over a 16hr period which is advised to be applied first thing in the morning and removed 
prior to going to bed. 
 
Inhalers: These resemble a cigarette and into the inhaler are placed cartridges containing 
nicotine which are then inhaled using a similar action to smoking. The inhaler is made up 
of a mouth piece and a replaceable nicotine cartridge.  When the patient draws on the 
mouth piece of the nicotine inhaler the cartridge releases nicotine which helps relieve 
cravings while at the same time the patients hands are kept busy. The inhaler available in 
Ireland is the Nicorette inhaler. It is recommended that 6 to 12 cartridges be used per day 
and it is particularly useful for those smokers that miss the hand to mouth movements of 
smoking.  
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Gum: This comes in two strengths 2mgs and 4mgs and this can be taken up to 15 times per 
day.  To release the Nicotine from the gum it should be chewed slowly until the taste 
becomes strong then the gum needs to be parked between the cheek and gums to allow for 
absorption of Nicotine.   Once the taste fades the gum needs to be chewed again to release 
more Nicotine and then parked again to allow for its absorption this can be repeated using 
the same piece of gum for about an hour after which it is recommended that you use a new 
piece of gum. Gum products available are NiQuitin Gum and Nicorette Gum both come 
in both strengths of 2 and 4mgs, Nicorette also produce an Icy White Gum which in 
addition to releasing nicotine helps to improve teeth whiteness. 
 
Micro Tabs/ Lozenges: 
Nicorette Micro Tab is a sublingual nicotine replacement tablet.  It is particularly useful 
for those who want a discrete delivery of nicotine.  A tablet is placed under the patients 
tongue and allowed to slowly dissolve.  Patients are instructed not to swallow chew or suck 
the tablet, nicotine will be released and absorbed through the lining of the mouth.  It only 
comes in one strength and it is recommended that smokers who smoke less that 20 per day 
use one Micro Tab per hour while those who smoke more than 20 per day may take 2 
Micro Tabs per hour the amount not to be exceeded per 24hrs, being 40. 
 
NiQuitin Lozenges: These come in 2mg and 4mg strength and it is recommended that the 
more heavily addicted smoker use the higher dose.  The recommended dose is 1 lozenge 
every one to two hours about 9 per day but can be used up to a maximum of 15 lozenges 
per day. 
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NiQuitin Mini: These are small mint flavoured Nicotine Lozenges that relieve Nicotine 
cravings within minutes and deliver their full dose 3 times faster than gum.  There are 2 
doses of NiQuitin Minis available 1.5mg and 4mg.   It is recommended that if you smoke 
less than 20 cigarettes per day that you use 1.5mg and that if you smoke over 20 cigarettes 
per day that you use the 4mg. 
 
Varenicline (trade name Champix) Tablets contain the active ingredient Varenicline.  
Varenicline is a type of medicine called a nicotinic acetylcholine receptor partial agonist. 
This means that it acts on the same receptors in the brain as nicotine. Varenicline works by 
stimulating the nicotinic receptors in the brain.  
When you smoke a cigarette, the nicotine quickly reaches your brain and tells certain 
receptors there to start releasing dopamine, a chemical that makes you feel good. What 
Varenicline does is stop those receptors from responding to the nicotine. That means you're 
not going to get that "rush" or "buzz" normally associated with smoking. Once the ‘buzz’ is 
gone, the temptation to sneak a cigarette is going to be less and less. Varenicline has high 
and selective activity at alpha4–beta2 receptor. It is a partial agonist at this receptor in vivo 
producing a lesser response than that of nicotine (30–60%) but also blocks the effect of any 
nicotine added to the system (Jiloha, 2010).  Thus, Varenicline maintains a moderate level 
of dopamine release, which reduces craving and withdrawal symptoms during abstinence.  
It also blocks the reinforcing effects of nicotine obtained from cigarette smoke in the case 
of relapse. 
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Champix is only available on prescription.  A complete course of treatment is for 12 weeks.  
It is prescribed as a 2 week starter pack during which time the smoker may continue to 
smoke but the smoker needs to set a quit date between day 8 and day 14 of the treatment.   
Day 1 – 3  One 0.5mg tablet to be taken in the morning. 
Day 4 – 7  One 0.5mg tablet to be taken twice daily, in the morning and once in the 
evening at about the same time each day. 
Day 8 - 14  One blue 1mg tablet to be taken twice daily, one in the morning and one in 
the evening at about the same time each day.  This dose is continued from week 3 to week 
12. The prescription for the 2nd and 3rd months comes in a continuation pack. 
It is recommended that patients complete a 3 month course of Champix.  There is also 
evidence that if successful for 12 weeks a further 12 weeks of treatment has added 
advantage in preventing relapse. 
 
Bupropion (trade name Zyban).  The recommended treatment period is 7 to 9 weeks. 
Dosage: Initially 150mg once daily for 6 days then 150mg twice daily (8hrs apart) for the 
remainder of the 7 – 9 weeks. During the first 2 weeks of treatment the smoker continues to 
smoke but should be aware when commencing the treatment that their quit date will be 2 
weeks into the treatment period.  The maximum single dose is 150mgs and the maximum 
daily dose is 300mgs. 
Neither Varenicline nor Bupropion should be offered to young people under 18 nor to 
pregnant or breastfeeding women.  
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Other methods of treatment available for smoking cessation are; Acupuncture, 
Hypnotherapy and Rapid smoking, a form of aversion therapy.  For both hypnotherapy and 
acupuncture there is evidence that they do not improve long term quit status more than a 
placebo.  As far as rapid smoking goes there is good evidence that this can improve 
abstinence rates but it is not recommended as it conflicts with smokefree regulations 
(NICE, 2008). 
 
Quitlines  
 
Quitlines have been shown to be effective and there is a national Quitline in Ireland which 
is run by the Health Service Executive in conjunction with the Irish Cancer Society.  
Several meta-analysis have established that proactive telephone counselling is an effective 
intervention for smoking cessation (Keller et al., 2010). Quitlines have the advantage of 
being able to reach a large number of the population.  Overall quit rates achieved by 
patients using different interventions are shown in figure 3.2 
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Figure 3.2  Different interventions used by smokers reporting continued cessation for 6 
months. 
 
Reproduced from (WHO, 2011) 
 
3.6 Cessation rates 
 
In the Lung Health Study of patients with chronic obstructive pulmonary disease (COPD) 
the effect of smoking cessation was striking; and it showed that the development of 
clinically significant airways obstruction was largely prevented in those who quit as 
compared with those who did not.  It also showed beneficial lung function improvements in 
both sexes and concluded as a result that it is probably ‘never too late’ to use cessation as 
an intervention for COPD (Anthonsien, 2004). 
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In a study carried out in the UK which was published in 2000, it was shown that by 1990 
smoking cessation had almost halved the number of lung cancers that would have been 
expected if the former smokers had continued. It also showed that people who 
stopped smoking, even well into middle age, avoid most of their subsequent risk 
of lung cancer, and stopping before middle age avoids more than 90% of the risk of lung 
cancer attributable to tobacco (Peto et al., 2000). 
In the UK between 2003 and 2006 over 800,000 smokers availed of the NHS smoking 
cessation services. Between 2005 and 2006 of those who set a quit date 55 % had quit at 4 
weeks.  The cost to the NHS per quitter for delivery of this service was £158.00 (The 
information Centre, 2006). 
Intervention from health professionals has been shown repeatedly, in randomised controlled 
trials, to increase the percentage of smokers who stop and remain abstinent for 6 months or 
more (West et al., 2000). 
Approximately one in three European smokers have tried to quit in 2008 and of those that 
have tried 51% remained abstinent for less than or equal to 56 days, 28% remained 
abstinent for 1 to 8 weeks, only 19% remained abstinent for more than 8 weeks and <5% of 
these can be expected to be successful at 12 months (Andreas et al., 2009). 
 
3.7 Predictors of successful quit rates 
 
Possible predictors of successful quit rates are many and varied such as:   Gender, age, 
socio-economic group, smoking status (level of addiction), family environment, treatment 
offered, medical advice, primary reason for quitting, number of previous quit attempts, 
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support and or pharmacological interventions.  The ability of the individual to pay for 
treatment or whether the treatment is available free to some individuals may also impact on 
successful quit rates. 
Quitting produces immediate and significant health benefits and reduces most of the 
associated risks within a few years of quitting (General, 1988). 
In the USA studies show that successful quitters were more likely to be well educated at 
least to college level, have rules against smoking in their homes, be less likely to have 
switched to light cigarettes for health concerns, and more likely to be aged 35 years or 
older, and be married or living with a partner  (Lee and Kahende, 2007). 
 
3.8 Validation of quit status 
 
3.8.1 Cotinine:  
Cotinine is a breakdown product of nicotine and therefore is a reliable biomarker for 
nicotine and this makes it an accurate way of measuring exposure to tobacco smoke. 
Cotinine levels can be measured in blood, urine, hair and saliva and levels can be measured 
to validate smoking status.  The most common sample for cotinine measurement is saliva 
due to ease of sampling.   More often cotinine levels are not used as a means of validating 
quit status as it is time consuming and expensive but is used extensively in population 
studies e.g. detection of exposure to secondhand smoke in children.   
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3.8.2 Breath carbon monoxide measurement and smoking: 
 
Carbon monoxide is a gas that is released from burning tobacco. When it is inhaled it enters 
the blood stream and interferes with the working of the heart and the blood vessels. Carbon 
monoxide (CO) is a colourless, odourless gas that is produced as a result of incomplete 
combustion of carbon-containing materials, such as tobacco and is thus a very important 
metric to quantify (McCaffrey et al., 2012).   Up to 15% of a smoker’s blood can be 
carrying carbon monoxide instead of oxygen.  The level of carboxyhaemoglobin (COHb) in 
the blood has also been shown to be a useful marker of tobacco smoke absorption (Wald et 
al., 1981). 
The breath CO monitor is a good tool for use in smoking control assessments and a reading 
greater than 5 ppm strongly suggests that the patient is a smoker and on questioning those 
whose readings were between 5.5 and 18ppm admitted having smoked a cigarette on the 
day of the test (Low et al., 2004). This is the validation method of choice for smoking 
cessation services due to its low cost, ease of use and instant results.  Most cessation 
services use CO monitors for validation purposes and this is strongly recommended. 
 
3.8.2.1 Equipment – CO monitor  
 
Most cessation treatment providers use co monitors to validate a patient’s quit status. 
The one I use when treating is the Care fusion CO monitor.  
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3.8.2.2 Method 
 
A patient is instructed to take in a deep breath, hold it for at approximately 20 seconds and 
then exhale slowly and completely into the CO monitor. The monitor displays parts per 
million (PPM) of Carbon Monoxide on its clear LCD display, and when used in 
conjunction with the smoking cessation guide chart, %COHB are readily available. 
The CO Monitor features single-button operation and coloured light indicators to simplify 
patient understanding of the process: 
 Green: 0 to 6ppm 
 Amber: 7 to 10ppm 
 Red:  11 to 20ppm 
 Flashing red and alarm: >20ppm 
 
3.8.2.3 Calibration of CO monitors 
 
CO Monitors do not need frequent calibration and usually they come with a guarantee from 
the manufacturers saying that the factory calibration is valid for 6 months.  Once this time 
has passed they need to be sent back to the manufacturers for re-calibration or if the 
calibration gas is on site they can be calibrated in a medical physics department.  It is 
recommended that they are calibrated every 6 months to ensure accuracy. 
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3.8.3 Self-Reported  Quit Status 
 
Many cessation treatment providers gather their quit rate statistics by telephone 
consultations.  This means that a lot of the quit rates recorded are self-reported by the 
patients and this has its limitations.  An example of this self-reporting limitation was 
demonstrated in a study of primary care patients with COPD where it was shown that they 
do not provide valid information on their smoking status, which hinders the service 
providers ability to provide adequate therapeutic interventions (Hilberink et al., 2011).  Use 
of biochemical validation either by monitoring of breath CO or measurement of cotinine 
levels in daily care could overcome this problem. 
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CHAPTER 4   STUDY METHODOLOGY 
 
In this chapter I will discuss the development of a smoking cessation providers database, a 
national census of the cessation services which will assess their range and availability, the 
development of a cessation treatment database, pilot of its use and a patient satisfaction 
questionnaire for the service they attended.  In each of the above I will outline the methods 
used, the populations surveyed and or treated and the instruments used to do so.  All data 
collected stored and analysed in this study were treated with care and consideration for the 
patients and service providers from whom they were collected.  All computers used had 
secure usernames and passwords and were protected by Symantec endpoint.  Data were 
stored on a secure password protected server which is stored in a network operations centre 
(NOC).  The NOC is a secured locked room with restricted access. 
 
4.1 Study plan  
 To establish a comprehensive database of cessation service providers. 
 Census of services including patient numbers, referral paths and training of service 
providers. 
 A data collection tool/treatment database for use by service providers. 
 Piloting of data collection instrument/treatment database and analysis of data gathered 
using it. 
 A patient satisfaction survey of the service they received for smoking cessation. 
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Gant Chart: This project was designed to run over a 30 month period to include several elements 
Months 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Refine and futher develop 
Database of Cessation service 
providers
Development of Census 
questionnaire to access range 
and availability of services and 
guidelines 
Pilot Census Questionnaire
Analyse and revise Census 
questionnaire
Circulate Census Questionnaire 
& collect data
Data Entry of Census 
Questionaire data
Develop a smoking cessation 
treatment data collection 
Instrument( Treatment database)
Develop Guidelines for 
completing Treatment database
Organise and conduct 
Workshops nationally for 
cessation service providers
Circulation of Treatment 
databases along with guidelines 
and Patient satisfaction 
questionnaires
Treatment data collection 
cleaning and entry
Annalysis of treatment data 
base and patient satisfaction 
survey.
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4.3 A database of smoking cessation service providers:  
Targeting, validating and expanding on the number of service providers identified in a 
previously developed database.   
 
4.3.1 Instrument: Excel Based Database. 
The database of Ireland’s smoking cessation service providers was to be a full and 
comprehensive one of existing services including the location of service, name of service 
providers, their contact details, phone, email addresses and details of the line managers.  
For the purposes of the development of a smoking cessation services  database, a smoking 
cessation service was defined as a service that could be based in a healthcare or community 
setting, providing a service either on an individual one to one basis,  over the telephone or 
in a group, that the service be delivered by a specially trained person who will give smokers 
the knowledge and support required to change their smoking behaviour in such a way as to 
increase their chances of a successful quit attempt (Currie et al., 2010). 
 
4.3.2 Methods 
An existing incomplete Irish Health Promoting Hospitals Network database of hospital 
based service was provided to TFRI and this database was then expanded and updated.  An 
advertisement  was placed in Health Matters which is a Health Service Executive science 
newsletter which provided a description of the project and a request for contact details with 
regard to known smoking cessation services be sent on to TFRI.  In an effort to identify 
services in General Practice contact was made with the Irish practice nurses and the Irish 
64 
 
College of General Practitioners.  All known private health care clinics and hospitals were 
also contacted to establish the existence of any private services.   
Every effort was made to ensure that the database was as comprehensive as possible so that 
the reliability of the planned census of cessation services would be valid. 
 
4.4 National census questionnaire 
A census of all known smoking cessation programmes was undertaken to assess the range 
and availability of smoking cessation services nationally. 
Population: 93 smoking cessation programmes were identified through HSE and HPH 
Network and from further research by TFRI which completed the database of all known 
smoking cessation programmes for this project.  
 
4.4.1 Survey Instrument: Questionnaire 
A previously validated questionnaire was sought in UK, Canada and elsewhere via 
Globalink - an online international Tobacco Control network.  As there was not an 
appropriate validated survey tool available to us a questionnaire of our own was developed 
(Appendix 1).  This questionnaire was developed in partnership with TFRI and members of 
the Irish Health Promoting Hospitals Network (IHPHN), Institute of Public Health (IPHI) 
and the Health Service Executive (HSE). Questions covered the following areas:  
 Background and training of staff providing the service 
 Range, intensity and frequency of services offered 
 Service setting, location and resources 
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Once the questionnaire was designed it was piloted among 6 cessation service providers to 
test its validity and they were asked to return completed questionnaires within 2 weeks 
commenting on the appropriateness of questions, its ease of completing and any content 
that they felt was not covered.  Following the piloting of the questionnaire comments from 
the service providers were discussed with staff from TFRI, and IHPH and the questionnaire 
was subsequently revised and modified as appropriate. The questionnaire and explanatory 
letter on how to complete it were mailed to all known smoking cessation facilitators in 
electronic format to 77 cessation service providers and by hard copy in the post to 16 
cessation service providers where it was established that they did not have access to a work 
computer or email address. Respondents were asked to return the completed questionnaire 
by email or by post to the TFRI office when email was not available to them. 
 
4.4.2 Delivery/Reminders:  
Up to two reminders were sent to programme facilitators one week post deadline and a 
second 2 weeks post deadline, to return the questionnaire. These were then followed up by 
at least 2 phone calls in a bid to get as large a response as possible.  
 
4.4.3 Data Quality:  
Quality control procedures for data entry were put in place including checking data fields 
for invalid entries, crosschecking dates to ensure that they were within the time frames 
required as well as double entry for all responses. 
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4.4.4 Data Analysis:  
Data were inputted by hand directly from the electronic and hard copy version of the 
questionnaires into excel.  Data were entered with double entry for accuracy and analysed 
using Statistical Packages for the Social Sciences (SPSS Version 19.0) which provided the 
descriptive data presented. 
 
4.5 Smoking cessation treatment data collection instrument (treatment 
database)  
A data collection instrument was developed to allow for the assessment of smoking 
cessation programmes.  A convenience sample of 1,490 patients was recruited cross-
sectionally while attending smoking cessation (SC) services throughout Ireland for a 3 
month period in 2008.  All but two of the service providers who participated in the pilot of 
the treatment database did so between January and April while two others who had delays 
in starting its use  piloted the treatment database between and May and August. 
 
4.5.1  Getting ‘buy in’ of smoking cessation service providers: 
Convening and conducting workshops for smoking cessation facilitators/co-coordinators: 
Three workshops were held nationwide, in Limerick, Dublin and Sligo. These workshops 
were hosted by the HPH Network and TFRI staff.  Using the newly completed and a now 
comprehensive database of the 93 smoking cessation SPs, they were all contacted and 
invited to the workshop location which would be most convenient for them to attend. The 
purpose of the workshops was to get agreement and “buy in” from smoking cessation SPs 
to participate in the study and to complete the treatment data collection instrument 
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(treatment database) (Appendix 2) for all patients attending their service over a 3 month 
period.  At these workshops TFRI and staff from HSE and HPH demonstrated the use of 
the data collection instrument.  Guidelines/instructions were written (Appendix 3) for 
completing/entering data into the database and these were circulated among the 93 service 
providers prior to the workshops.  At each workshop time was taken to go through the 
guidelines/instructions in detail with the SPs.  They were also given time to handle and 
enter data into the treatment database and any concerns or queries they raised were dealt 
with. The coding systems of the data collection instrument as well as the patient satisfaction 
questionnaire were explained.    
 
4.5.2 Instrument: Excel database. 
Using best practice criteria from the literature, the NICE guidelines, looking at existing 
datasets from Northern Ireland and Denmark as well as those used by some of the Smoking 
cessation service providers in Ireland, TFRI in consultation with HSE, IPH, and HPH 
developed a data collection instrument.  In particular it was found that the most 
comprehensive dataset which was being used in Ireland at the time was by the smoking 
cessation services in the North West.  The data collection instrument was designed to 
collect all relevant information in a format that was quick and easy to complete.  In its 
design, cognisance was taken of the need for a simple and timely completion method in 
order to aid compliance.  The instrument was designed to gather information such as 
whether the patient had previous quit attempts and if so whether they used Nicotine 
Replacement Therapy and whether the patient availed of one to one or group counselling, 
the number of visits to the cessation service, smoking profile, level of addiction and referral 
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source.  It also was designed to gather patient demographic details such as sex, age and 
social class and follow up information on patient smoking status at 4 weeks and 3 months. 
With regard to monitoring patients, the Russell Standard from the UK was detailed, which 
has been adopted as guidance. It specifies times during which follow-up reviews should 
take place. To save time, the data tool was programmed to automatically generate dates 
indicating the start and end of the 4 week and 3 month follow up periods according to the 
Russell Standard once a quit date has been entered.  
 
Each service provider was given their own unique identifying code which was developed 
using a minimum of 2 letters per centre. The first patient entered was given the added 
numerical identity of 001, e.g. a code would read AA001, and the last code allocated was 
ZZA001.  These codes were for use when entering patients into their system to protect the 
identity of the patient/patients being entered. 
 
4.5.3 Recruitment of subjects  
A study of all patients attending participating smoking cessation programmes was 
conducted. 
 
4.5.4 Population:  
The population consisted of all consenting patients attending the 49 participating smoking 
cessation programmes during the 3 month pilot use of the treatment database. Data on 1490 
patients were collected. 
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The data collection instrument/treatment database with guidelines was circulated to the 
participating 49 smoking cessation service providers. The co-ordinator/service providers 
were asked to collect data for each patient attending their smoking cessation service during 
the 3 month pilot period. Data were collected at the point of entry to the service. To 
ascertain whether a patient has remained abstinent, the co-ordinator needed to contact each 
patient at 4 weeks and 3 months after the patient has completed the smoking cessation 
programme.  It was requested that this contact be done in person where possible to enable 
CO validation of their smoking status so as to enable recording of patient quit status into 
the treatment database. The data were collected electronically on an Excel based spread 
sheet.  Each of the 49 participating service providers was emailed their personalised 
treatment database. The cessation providers returned the uniquely coded anonymised 
patient data sets to the study centre at TFRI.  Data received from 39 providers were suitable 
for analysis, the 2 databases received which were unsuitable for analysis used an Access 
database and it was not possible to match the variables from the 2 different data sets and so 
they had to be excluded from the analysis.  The remaining 8 providers who had initially 
agreed to participate failed to do so. 
Timeframe for data collection:  A three month entry period whereby data on all patients 
who consented to be a part of the project and were using the smoking cessation service was 
collected.  Each patient was “followed up” at 4 weeks and 3 months post their quit date 
during the smoking cessation treatment programme and cessation service providers were 
asked to validate the patients smoking status at these designated times by using a CO 
monitor.  These readings were to be taken by each service provider.  A successfully 
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validated reading was deemed to be <6ppm and a failed quit attempt was deemed to have a 
reading of >7ppm (Middleton and Morice, 2000). 
 
4.5.5 Main outcome measures: 
The main outcome measures of the treatment database were the 4 week and 3 months quit 
rates. Definition of quit used at 4 weeks: According to the Russell Standard, a patient is 
counted as a ‘4 week quitter’ if they have been assessed 4 weeks after their quit date (minus 
3 days or plus 7 days) and declares that he/she has not smoked a single puff on a cigarette 
in the past 2 weeks. 
Definition of quit used at 3 months: A patient is counted as a ‘3 month quitter’ if they 
have been assessed 3 months after their quit date (minus 14 days or plus 14 days) and 
declares that he/she has not smoked more than 5 cigarettes in the past 10 weeks. 
Other covariates studied were:  
 Demographics: Gender /Age/Ethnicity. 
 Pregnancy status 
 Referral source of patients 
 Patient status i.e. in patient/community/outpatient 
 Smoking History 
 Fagerstrom Score is a method of measuring the degree of tobacco addiction/dependency 
 0-3 mild level of addiction; 4-5 moderate level of addiction; 6-10 high level of addiction. 
 Treatments used on this attempt and on previous quit attempts 
 Number of previous quit attempts 
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 CO Validation; Service providers were asked that CO validation should be attempted on all 
patients who have said they are quit at their 4 week follow-up/review CO monitoring of 
patients at the 4 week and 3 months follow-up stage is considered to be good practice, as it 
is motivational for patients as well as a validation of their smoking status 
 Occupation/Social Class. The entire population was classified into one of the following 
social class groups (introduced in 1996) which are defined on the basis of occupation: 
1. Professional worker 
2. Managerial and technical 
3. Non-manual 
4. Skilled manual 
5. Semi-skilled 
6. Unskilled 
7. All others gainfully occupied and unknown 
The occupations included in each of these groups have been selected in such a way as to 
bring together, as far as possible, people with similar levels of occupational skill. In 
determining social class no account is taken of the differences between individuals on the 
basis of other characteristics such as education. Accordingly social class ranks occupations 
by the level of skill required on a social class scale ranging from 1 (highest) to 7 (lowest). 
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4.6 Patient satisfaction questionnaire  
 
4.6.1 Population:   
All patients who were treated during the pilot of the treatment database were asked to 
complete a satisfaction questionnaire. A sample of patients from each smoking cessation 
programme who indicated their willingness to participate in a satisfaction survey as well as 
signing the relevant consent form. 
 
4.6.2 Survey Instrument: A specially developed, self-administered questionnaire 
(Appendix 4).  
Timeframe for data collection: Patients were asked to complete a previously piloted 
questionnaire once they had completed the smoking cessation programme.  These were all 
patients entered into the treatment programme during the 3 month pilot of the treatment 
data collection instrument who agreed to complete the satisfaction questionnaire.   
All patients who agreed to complete the satisfaction questionnaire were issued with them 
by their smoking cessation provider either by hand on entry into the treatment programme 
or by post on completion of their treatment. They were requested to return the completed 
questionnaires anonymously to the research institute TFRI and not to their providers of 
care.  The questionnaires were issued with the same corresponding unique code as the code 
used entering their data for the 3 month trial of the treatment database. The anonymity of 
the patient was maintained at all times using these unique identifying codes which were 
issued in batches to the providers who then allocated them to the patients.  No data was 
received from providers with either names initials or addresses of patients.  This was done 
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with a view to comparing the satisfaction questionnaires with the outcome of their 
treatment while at all times protecting their personal individual identity.  At the time of 
issue of the patient satisfaction questionnaire by the provider to the patient they were also 
given a stamped addressed envelope to TFRI which they posted themselves and did not 
have to hand back to their service provider. 
4.6.3 Delivery/Reminders:  
It was requested that at least 1 telephone reminder  (at 1 week post treatment completion or 
failure to return for follow up) be made requesting patients to return questionnaires. 
4.6.4 Data Quality:  
Quality control procedures for data entry were put in place including double entry for all 
responses allocation of unique identifier, reconciliation of survey response with treatment 
data already collected and identifying code verification.  
4.6.5 Data Analysis:  
 
Data were entered directly into SPSS by hand from the 342 hard copies received by post of 
the patient satisfaction questionnaires and this statistical package was used to analyse data 
findings. 
4.6 Ethics submission and approval.   
 
Various ethical approval committees were considered and an ethics submission was made 
to the SJH / AMNCH RESEARCH ETHICS COMMITTEE for approval of the project on a 
national basis. A study protocol was put together and submitted along with the completed 
ethics application form.  During completion of the ethics approval application form a 
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patient information sheet was developed along with a patient consent form.  The completed 
application form, information sheet and consent form were submitted and approval was 
received (Appendix 5).   
4.7.1 Subject consent/subject information sheet  
 
All patients attending smoking cessation services were asked permission to have their data 
entered into the electronic database which was being piloted over a 3 month period and to 
complete a patient satisfaction questionnaire in relation to the smoking cessation service 
they had received.  If they were agreeable then they were given an information sheet and 
consent form to sign giving permission for their data to be entered into the local database 
and then to be sent to and be analysed by TFRI.  
After consultation with cessation service providers around the country some individuals 
raised concerns with regard to approval of the project on a national basis and requested that 
Ethical approval be sought in their individual institutions.  This applied to St. Vincent’s 
Hospital, Beaumont Hospital and the Mater Hospital.  Further ethical approval was sought 
and received by each of the above although St. Vincent’s Hospital decided not to 
participate in the pilot use of the treatment database as they felt that their patients would not 
be able to understand the information provided and thus would be unable to give their 
consent. 
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CHAPTER 5    RESULTS 
 
In this chapter results will be presented on all 4 limbs of the project. 
1. Smoking cessation service database 
2. Census of smoking cessation services in Ireland 
3. Pilot of treatment database 
4. Patient satisfaction questionnaire 
 
5.1 Smoking cessation service database 
Once all avenues of enquiry were exhausted a finally completed database on which data 
was gathered on 93 smoking cessation service providers (SPs).  No service providers were 
identified in private health clinics.  The database contains the name of the service provider, 
location of the service and contact details including address, phone number and email when 
available.  
5.2  Census questionnaire analyses 
5.2.1  Sample: 
 
Of the possible 93 cessation SPs  canvassed, it was established that questionnaires could be 
sent for completion electronically by email to 77 cessation SPs  and 16 were sent out for 
completion by hard copy in the ordinary post because email addresses were not available.  
Following the sending out of the questionnaires two follow up phone calls were made 
where it was established that 13(14%) of cessation SPs needed to be removed from the list 
of possible responders due to extended leave, shared service coverage or discontinuation of 
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service.  Therefore a population of 80 eligible cessation SPs were thought to constitute the 
population for this survey. Of these 68 responded to the questionnaire, giving a response 
rate of 85%.   
 
5.2.2  Training of service providers 
All 68 SPs had some specific training in smoking cessation with more than 2 years’ 
experience and are employing evidence based interventions. 62.1% (n=41) expressed a 
need for further training while 37.9% (n=25) were happy with their current level of 
training.  
Graph 5.1 Most recent training received by service providers. 
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Table 5.1 Most recent training received by SPs. 
Date of last Training Frequency % 
Pre 2000 2 3 
2001 0 0 
2002 2 3 
2003 6 9.1 
2004 9 13.6 
2005 9 13.6 
2006 23 34.8 
2007 15 22.7 
Total 66 100 
 
27.3% (n=18) within last 3 to 4 yrs. 
15.2% (n=10) 4 or more years ago. 
Showing most SPs had received training in the last 2 years at 57.9% (n=38) 
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Graph 5.2 Identifying the training needs that the SPs feel they require. 
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Table 5.2  Training needs as identified by SP’s 
Identified training Needs  %  Number
Non identified 45.6% 31 
Interviewing techniques 10.3% 7 
Training of trainers 8.8% 6 
Smoking Cessation for youth 7.4% 5 
Smoking Cessation for mental 
health 7.4% 5 
Facilitation skills 4.4% 3 
Certified SCT 4.4% 3 
Information on Champix 2.9% 2 
Clinical supervision 2.9% 2 
Maudseley training 2.9% 2 
Multiple addictions 1.5% 1 
Intensive smoking cessation 1.5% 1 
 
The top training needs identified were, 10.3% (7) of SP’s felt they needed further training 
in interviewing techniques and 8.8% (6) felt they needed to learn more on how to deliver 
further training to smoking cessation trainers. 
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5.2.3  Professional Background of service providers: 
Graph 5.3 The spread of professional backgrounds of SPs 
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Table 5.3  Showing professional background of SP’s 
Professional 
Background % Number 
Nurse 71.2% 47
Health Promotion 19.7% 13
Community Worker 1.5% 1
Medical Doctor 1.5% 1
Physiotherapy 1.5% 1
Pharmacy 1.5% 1
Environmental Health 1.5% 1
Addictions Counsellor 1.5% 1
Total 100.0% 66
 
The top 2 professional backgrounds for cessation service providers were: 
71.2% (n=47) Nurse and 19.7% (n=13) Health Promotion. 
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5.2.4  Service availability 
Graph 5.4 Populations to whom the cessation services declared they were available 
 
Table 5.4  Populations to whom the cessation services declared they were available. 
Populations to whom services 
available % Number 
All Population Groups 42.9% 27 
In patient /Staff and Community 23.8% 15 
Out Patient/Staff & Community 20.6% 13 
In Patient/Out Patient and Staff 7.9% 5 
Out Patient & Community 3.2% 2 
In Patient and Staff 1.6% 1 
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The top 3 population groups served by cessation providers were: 
42.9% (27) All population groups 
23.8% (15) In patient/staff & community 
20.6% (13) Out patient/staff & community 
There was only one cessation service that said they were exclusively for the use of 
inpatients and staff. 
 
5.2.5  Services provided 
 
It was known that both telephone, one to one and group therapy was being offered but to 
what degree was not known. 
 
Graph 5.5 Types of services provided 
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Table 5.5  Types of smoking cessation services provided. 
Types of Service Provided Frequency % 
Individual advice & 
Counselling 62 98.4%
Group Advice 39 61.9%
Telephone Advice 57 90.5%
 
Almost all of the 68 respondents provided individual advice & counselling and telephone 
support but only 61.9% (n=39) provide group advice or counselling. 
 
5.2.6  Duration of consultations: 
 
Initial individual sessions showed a mean duration of 40 min (range 10 -90mins).  
Individual review sessions showed a mean duration of 23 min (range 5–60mins). 
60% (n=38) provided individual support on a weekly basis. 
Initial telephone sessions had a mean duration of 15 min and review sessions with a mean 
duration of 6 min. 
 
5.2.7  Patient follow up: 
 
There was not a standardised follow up identified, other than by the North Western region 
which represents 9.5% of the country’s smoking cessation services. 
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Graph 5.6 How many providers follow up patients? 
 
57.1% (n=36) follow up all patients, 38.1% (n=24) follow up some patients (*specifically 
those who have set a quit date), while only 4.8% (n=3) do not follow up any individuals. 
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How service providers set out their planned review of patients attending a smoking 
cessation service: 
Graph 5.7 Schedule of follow up contacts with patients: 
 
Table 5.6  Schedule of patient follow up visits 
Follow up schedules % Frequency 
2 Week follow up 54.8% 34
1 Month Follow up 48.4% 30
3 Month follow up 75.8% 47
6 Month follow up 45.2% 28
1 Year follow up 69.4% 43
 
Most common follow ups are conducted at 2 weeks 50% (34), 3 months 75.8% (47) and 1 
year 69.4% (43). 
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5.2.8 Use of CO monitor as a means of validating quit status of patients: 
Graph 5.8 Number of providers who use CO as a means of validating quit status 
 
Table 5.7  Frequency of CO Validation by SP’s 
Frequency of  CO Validation % Frequency 
Never 27.0% 17 
Rarely 12.7% 8 
Sometimes 23.8% 15 
Often 15.9% 10 
Always 20.6% 13 
Total 100% 63 
 27% (17) Never use CO validation. 
 36.5% (23) Rarely or sometimes use CO validation. 
 36.5% (23) Use it often or always. 
  
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5.2.9  Geographical spread of services 
Graph 5.9 Regional spread of hours of cessation service per week 
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Table 5.8  Hours of service per week in the different regions 
Province/Region 
No. of 
Responses 
No. 
hours/week 
Proportion of 
total hours/week 
Dublin 17 212.5 20.10% 
Rest of Leinster 20 231 21.90% 
Connaught 7 80 7.70% 
Ulster 13 260.1 24.60% 
Munster 15 175 16.70% 
No region 
identified 
1 98 9.00% 
Totals 72 1056.6 100.00% 
 
Shows the distribution of services throughout the country in hours delivered.  The service 
in Dublin and the rest of Leinster represents 41% of the total hours of service reported in 
this survey (Currie et al., 2010). 
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5.2.10  Setting of smoking cessation services 
Graph 5.10 Setting of smoking cessation services. 
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Table 5.9  Where cessation services are delivered 
Setting of Service % Frequency 
General Hospitals 41.3% 26
Psychiatric Hospitals 1.6% 1
Maternity Hospitals 4.8% 3
G.P. Surgeries 12.7% 8
Other Primary Care settings 12.7% 8
Pharmacies 4.5% 3
Health Centres 20.6% 13
Community Centres 9.5% 6
Care of the Elderly 7.9% 5
Other settings 25.4% 16
 
47.7% (30) hours are hospital based.  There was only 1 psychiatric hospital identified as 
having a service. 
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5.2.11 Computer accessibility and data collection: 
Graph 5.11 How many service providers have access to computers? 
 
 
Almost 1/3rd of service providers 31.7% (19) have no access to a computer. 
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5.2.12  Data collection and analysis 
Graph 5.12 Data collected by service providers and whether it was analysed or not. 
 
 
A surprisingly large amount of data is collected by service providers and is not being 
reported on or analysed.  The largest amounts of unanalysed/unreported data collected are: 
Smoking frequency 57.8% (37) and number of previous quit attempts 53.1% (34) but even 
routine data such as age 39.1% (25) and gender 40.6% (26) are left unanalysed. 
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5.3  Smoking cessation treatment database 
5.3.1  Sample 
 
49 service providers agreed to participate in the pilot use of the newly developed treatment 
database.  Using this database a 3 month study was conducted of patients recruited cross-
sectionally while attending the 49 participating smoking cessation services throughout 
Ireland.   41 completed databases were received, 2 of which were not included as they were 
not suitable for analysis, the data was collected in an Access database and not in the 
specially developed Excel based database. It was not possible to match the data fields that 
these 2 providers collected in their own existing Access database as they differed too much 
from those set out in the piloted treatment database.  A total of 1,490 patients were 
recruited and subsequently analysed from the remaining 39 databases received.  A number 
of written and phone requests to the outstanding 8 service providers were made to no avail. 
This gave a response rate of almost 84%.   
 
5.3.2  Subject demographics  
 
Of the 1490 patients entered into the treatment database there was a fairly even gender split 
with 736 Females and 752 males treated, gender data was missing on 2 patients this gender 
split is in keeping with the statistics from the 2011 national census. 
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Graph 5.13 Males (n=752) Females (n=736) and total number of patients analysed. 
(n=1488) 
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Graph 5.14 Age distribution of the study subjects (n=1402). 
 
From a total of 1402 patients whose age was recorded this graph shows the spread of the 
age ranges captured during the 3 month pilot of the treatment database. Age was missing or 
incorrectly entered on 88 patients. The majority of patients were between 46 and 65 years 
of age. 
 
5.3.3  The overall quit rates recorded in the treatment database. 
 
Quit rates were recorded at 4 weeks and 3 months using the Russell Standard definition of 
quit, a patient was considered to have quit at 4 weeks if they were assessed (face to face, by 
postal questionnaire or by telephone) 4 weeks after their quit date and declared that they 
had not smoked a single puff on a cigarette in the past 2 weeks.  
97 
 
A patient was considered to have  quit at 3 months if they were assessed (face to face, by 
postal questionnaire or by telephone) 3 months after their quit date and declared that they 
had not smoked more than 5 cigarettes in the past 10 weeks. 
 
Graph 5.15 Quit rate (%) of all patients entered 
 
Table 5.10  Quit rate results at 4 weeks and 3 months 
  
Frequency 
Quit % 
Frequency 
Not Quit % 
4 Weeks 552 37% 936 62.8 
3 months 334 22.4% 1151 77.3 
 
The overall quit rates of those who attended for smoking cessation treatment regardless of 
setting a quit date, were 37% at 4 weeks and this rate fell to 22.4% at 3 months.   
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5.3.4  Setting of quit date 
 
Not all patients attending a service set a quit date.  Some may only be contemplating 
quitting and need to be motivated and helped in preparing for their quit attempt.  This next 
graph demonstrates how important it is to progress patients to this stage. 
Graph 5.16 Quit rates (%) amongst those who had set a quit date (n=890) compared 
to those who did not set a quit date (n=600). 
 
2 = 545.372a, (2) P < 0.05 at 4 weeks 
2 = 200.809a, (2) P < 0.05 at 3 months 
61% of patients who set a quit date (n=890) were quit at 4 weeks. This fell to 35% at 3 
months. Of those who did not set a quit date (n=600) there were 1.4% quit at 4 weeks and 
3.8% quit at 3 months. 
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Graph 5.17 Quit rates according to age ranges (n=1402) at 4 weeks and 3 months 
 
2 = 14.359a, (6) P = 0.053 at 4 weeks 
2 = 38.221a, (6), P < 0.05 at 3 months 
Table 5.11  Numbers of quit rates recorded within age ranges 
Data on age range Quit at Number % 
4 weeks 1402 94.1 
3 Month 1401 94 
 
Showing quit rates by age demonstrates that the older age groups are statistically more 
likely to quit than their younger counterparts at 3 Months. The quit rate in all age groups 
falls from 4 weeks to 3 months. 
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Graph 5.18 Quit rates according to age and gender 
 
2 = 14.102a, (2), P < 0.05 at 4 weeks. 
2 = 7.958a, (2), P < 0.05 at 3 Months. 
Graph 5.18 shows quit rates at 4 weeks to be 41.8% of Males and 32.4% of Females falling 
to 25.3.5% and 19.7% respectively at 3 months, showing that males have significantly 
higher quit rates compared to female quit rates in the study population for both time 
periods- 4 week and 3 months. 
5.3.4  Smoking history   
 
The number of cigarettes smoked per day and the Fagerstrom score were calculated and 
scored 0-3 low addiction, 4-5 medium addiction and 6-10 high addiction in order to 
determine the degree of addiction of each patient. 
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Number of cigarettes smoked daily: 
Out of a total of 1,436 patients whose daily smoking rate was recorded, 400 (27.9%) 
reported smoking less than 20 per day, while 1036 (72.1%) patients reported smoking more 
than 20 per day. While the exact number of cigarettes smoked per day was recorded for 
analysis they were divided into 5 different categories; 0-10, 11-19, 20-29, 30- 39 and 40+. 
 
Graph 5.19 Breakdown of number of cigarettes smoked by patients within the 
dataset 
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Table 5.12  Numbers of cigarettes smoked per day 
Numbers smoked per day Frequency % 
0 to 10 cigs per day 213 14.8 
11 to 19 cigs per day 187 13.0 
20 to 29 cigs per  day 656 45.7 
30 to 40 cigs per day 221 15.4 
40 plus cigs per day 159 11.1 
Total 1436 100.0 
 
Quit rates within number of cigarettes smoked. 
Graph 5.20 Quit rates according to number of daily cigarettes smoked 
 
2 = 8.452 (8), P = 0.391 at 4 weeks 
2 = 15.244 (8), P < 0.05 at 3 months 
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Quit rates according to number of cigarettes smoked by individuals was statistically 
significant at 3 months:  heavier smokers were shown to be more likely to remain quit at 3 
months 25.2% (n=159) than lighter smokers 22.2% (n=400) 
 
Fagerstrom score 
The addiction level of the smoker was recorded by calculating their Fagerstrom score.  This 
was recorded in 1440 of the 1490 patients entered.  This did not prove to be a statistically 
significant predictor of quit rates. 
 
Graph 5.21 Distribution of the Fagerstrom scores across the patient population in 
the dataset. 
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Table 5.13  Recording of Fagerstrom score 
Fagerstrom 
Scores 
Numbers % 
0-3 290 20.1 
4-5 428 29.7 
6-10 722 50.1 
Total 1440 100 
 
The largest portion of the dataset had a high Fagerstrom score of 6-10 @ 50 % (n=722) 
demonstrating a high level of tobacco dependency. 
 
Graph 5.22 Quit rates according to Fagerstrom scores 
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The quit rates according to the patients Fagerstrom score: while the results are not 
statistically significant it does show a trend for the higher the degree of dependency the 
lower the quit rate. 
2 =8.566a, (4), P = .073 at 4 weeks. 
2 =6.905a, (4), P = .141 at 3 Months. 
 
5.3.5 Social class/ occupation 
 
The entire population was classified into one of the following social class groups which are 
defined on the basis of occupation: 
1. Professional worker 
2. Managerial and technical 
3. Non manual 
4. Skilled manual 
5. Semi-skilled 
6. Unskilled 
7. All others gainfully occupied and unknown is used where no precise allocation is 
possible. 
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Graph 5.23 Social class/occupation groups within the dataset 
 
 
Table 5.14  Social classes within the dataset. 
Social class/occupation Frequency % 
Professional Worker 41 2.8 
Managerial & Technical 115 7.9 
Non Manual 237 16.3 
Skilled Manual 292 20.1 
Semi-Skilled 271 18.6 
Unskilled 264 18.2 
All Others 234 16.1 
Total 1454 100 
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Graph 5.24 Quit Rates (%) by Social Class/Occupation (n=1454) 
 
Quit rates by occupation was shown to be statistically associated with quit rate at 4 weeks 
and 3 months.  
2 =49.668a (12), P <0.05 at 4 weeks. 
2 =34.296a (12), P <0.05 at 3 months. 
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Table 5.15  Quit rates within SE groups 
 SE Groups 
Total within 
each group 
Quit at 4 
weeks 
Quit at 3 
months 
Professional Worker 41 13 10 
Managerial & 
Technical 115 61 42 
Non Manual 237 88 57 
Skilled Manual 292 125 79 
Semi-Skilled 271 121 64 
Unskilled 264 77 45 
All Others 234 58 31 
Total  1454 543 328 
 
When these were grouped into SE groups 1-3 this demonstrated quit rates of 41% at 4 
weeks and 28% at 3 months while SE groups 4-6 demonstrated quit rates of 39% at 4 
weeks and 23% at 3 months. 
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5.3.6  Patients primary motivation to quit 
 
Graph 5.25 Patient’s primary motivation to quit in the dataset. (n=1425) 
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Table 5.16  Patients Primary motivation to quit. 
Primary Motivation to 
Quit % Number 
Current Illness 27% 378 
Financial Gain 2% 31 
Pregnant 6% 90 
Freedom from Habit 4% 53 
Family/Children 3% 49 
Medical Advice 9% 146 
Health Gain 43% 607 
Improve Quality of Life 4% 60 
Other 1% 11 
Total 100% 1425 
 
Health was overwhelmingly the primary motivation to quit smoking at 69.1% (985) 
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Graph 5.26 Quit rates according to Primary reason for quitting 
 
2 =44.564a (16), P < 0.05 at 4 weeks. 
2 =22.956a (16), P = 0.115 at 3 Months 
Primary motivation for quitting is statistically significant at 4 weeks but does not seem to 
be a factor in maintaining abstinence at 3 months most notably in the motivation of 
‘financial gain’ which had a quit rate of 38.7% at 4 weeks and only 12.9% at 3 months. 
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5.3.7  Pregnancy 
118 patients entered into the database were reported as pregnant which represents 15.6% of 
the total female numbers. 
Graph 5.27 Number of pregnant and non-pregnant women within the dataset. 
 
 
Table 5.17  Pregnant and non-pregnant women. 
Pregnant Frequency % 
No 634 84.3 
Yes 118 15.6 
Total 752 100 
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Graph 5.28 Showing quit rates amongst pregnant and non-pregnant women. 
 
 
2 = 15.485 (2), P < 0.05 at 4 weeks. 
2 = 7.054 (2), P < 0.05 at 3 months. 
Of the 118 pregnant women the quit rate was 16.5% at both 4 weeks and at 3 months.   This 
compares with 35.2% at 4 weeks and 20.3% at 3 months of the non-pregnant female 
population in the study. 
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5.3.8  Quit rates by quitting method: 
 
Graph 5.29  Methods used to aid quit attempt. 
 
 
Table 5.18 Treatment methods used 
Method Used Number % 
Cessation programme 284 32% 
CP+NRT 458 51% 
CP & Combination therapy 11 1% 
CP+Zyban 1 0% 
CP+Champix 137 15% 
Total 891 100% 
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The most often used method by this cohort was smoking cessation treatment programme 
accompanied by nicotine replacement therapy in 52% (469) of the patients recorded. 
Graph 5.30  Quit rates according to methods used 
 
2 = 8.925a (8), P = .349 at 4 weeks. 
2 = 8.055a (8), P = .428 at 3 months. 
Quit rates using cessation programme only and cessation programme plus NRT fall off by a 
significant 33% and 30% respectively whereas the quit rate of those treated with Champix 
and cessation programme remained at 65% at both 4 weeks and 3 months.  The above data 
represents results of 891 of the total 1490 patients entered into the data base.  The 
remaining 599 who failed to return and commence treatment were reported as a failed quit 
attempt in the overall quit rates reported in this thesis which was 37% at 4 weeks and 22% 
at 3 months.  The quit date of those that had set a quit date and therefore commenced 
treatment, had a quit rate of 61% at 4 weeks and 35% at 3 months. 
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5.3.9 Quit rates according to number of previous quit attempts 
Graph 5.31 Number of previous quit attempts by patients in the dataset 
 
Table 5.19       Number of previous quit attempts. 
Previous quit attempts Frequency % 
Never 334 23.2 
≤3 827 57.6 
4 to 10 243 16.9 
>10 33 2.3 
Total 1437 100 
 
The most commonly reported number of previous quit attempts 
was ≤3 at 57.6%(827) 
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Graph 5.32 Quit rates (%) by previous number of previous quit attempts 
 
 
2 = 17.834a (6), P <0.05 at 4 weeks. 
2 = 9.755a (6), P = .135 at 3 months. 
 
When looking at the number of previous quit attempts the trend was for the more  
previous quit attempts the patients had the more likely they were to have a successful quit 
attempt at 4 weeks however this did not reach a statistically significant level  at 3 months. 
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5.3.10 Reporting/validation of quit status 
 
CO validation of quit status was missing on 867 patients in the dataset at 4 weeks and in 
1092 patients at 3 months. 
Graph 5.33 Reporting methods of quit status at 4 weeks and 3 months 
 
 
Most validations of quit status are by self-reporting 68% (427) at 4 weeks and 80% (320) at 
3 months. 
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5.3.11 Patient Status on referral 
The distribution of where patients were seen and whether they were treated as an inpatient 
or an outpatient in the dataset are described below.  
Graph 5.34 Patient status on referral  
 
Table 5.20 Patient status 
Patient Status Frequency % 
In Patient 620 41.7 
Out Patient 322 21.7 
Day Patient 22 1.5 
Public/Community 413 27.8 
Staff Members 86 5.8 
Mental Health 24 1.6 
Total 1487 100 
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Graph 5.35 Patient status and their quitting rates at 4 weeks and 3 months 
 
 
 
2 = 33.212a (10), P < 0 .05 at 4 weeks. 
2 = 14.306a (10), P = .159 at 3 months. 
Where patients were at the time of being treated was seen to be statistically significant in 
terms of quit rates at 4 weeks but not at 3 months.  In the case of inpatients the quit rate fell 
from 40% at 4 weeks to 24% at 3 months. 
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5.3.12   Referral source 
 
Graph 5.36 Referral sources of patients in the dataset 
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Table 5.21 Referral source of patients 
Referred by Frequency % 
Self 362 24.5 
Hospital Doctor 256 17.3 
Nurse/Midwife 697 47.2 
GP/Pharmacist 97 6.6 
Practice Nurse 4 0.3 
Quitline 8 0.5 
Mental Health Service 13 0.9 
Other 39 2.6 
Total 1476 100 
 
Neither the national Quitline nor practice nurses seem to refer patients to specialist 
cessation services on a regular basis and given the sample size of 1476 GP’s only referred 
6.6% of patients.  
  
 
 
 
 
 
 
 
 
 
 
123 
 
Graph 5.37 Patient referral sources and their respective quit rates at 4 weeks and 3 
months. 
 
 
 
2 = 14.531a (16), P = .559 at 4 weeks. 
2 = 14.359a (16), P = .572 at 3 months. 
Referral sources are varied and the success rate of the patients quit attempt is not shown to 
be more statistically successful in any category.   Self-referrals do have the highest quit rate 
at over 40% at 4 weeks, however they do have the biggest drop in quit rates measured at 3 
months.  
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5.3.13 Statistically associated covariates. 
 
Certain covariates were found to be statistically associated with quit rates. The following 
data were collected to demonstrate whether they had any bearing on quit rates at 4 weeks 
and 3 months. 
Table 5.22 Statistically associated covariates/factors influencing quit rates. 
 
Trends shown here were not statistically associated with quit rates however it shows a 
relationship with quit rates going in the one direction for example the higher the 
Fagerstrom score of patients the lower their quit rates and this may become statistically 
significant if numbers were greater and patients were followed for a longer period of time. 
 
 
125 
 
5.4 Patient satisfaction questionnaire: 
 
All data were inputted on a master Excel spread sheet from all completed patient 
satisfaction questionnaires received from patients of each of the 41 Smoking Cessation 
service providers.  
A total of 342 patients returned completed patient satisfaction questionnaires having 
availed of smoking cessation services during the 3 month pilot of the Data Collection 
Instrument (Patient treatment database). 
Of the 342 patients, all were above 18 years of age. Almost half were 18-35 years of age 
and 172 were females.  
 
5.4.1 Patient demographics 
 
Graph 5.38 Patient satisfaction gender distribution: Male 44.5% (138) Female 
55.5% (172) 
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Table 5.23 Numbers of Males and Females in the survey 
 
Gender Frequency % 
Male 138 44.5 
Female 172 55.5 
Total 310 100 
 
The data presented a reasonably even split between males and females (CSO 2011 census F 
49.9% and M 50.6%).  There was gender data missing on 9.4% of the completed 
questionnaires. 
 
5.4.2  Patient preferences for day and time of service. 
The majority preferred weekdays to weekends and also morning hours for seeking advice.  
Less than 7% of the patients had to wait for more than 4 weeks for an appointment with the 
smoking cessation service. 
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Graph 5.39 Patients appointment preference weekends or weekdays 
 
 
 
Table 5. 24 Weekday/Weekend preference 
Preference Frequency % 
Weekends 79 23.9 
Weekdays 252 76.1 
Total 331 100 
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Graph 5.40 Preference for time of day of service 
 
 
 
Table 5.25 Patients preferences of appointment times 
Preference for Time Frequency % 
Mornings 165 49.4 
Afternoons 65 19.6 
Evenings 103 31.0 
Total 332 100.0 
 
The majority of patients 49% (164) preferred their appointments to be held in the mornings 
while 31% (103) preferred evening clinics and the least popular time was afternoons which 
was preferred by only 19% (65) of patients. 
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5.4.3 Length of time awaiting appointment 
Graph 5.41 Waiting time for appointments 
 
Waiting time for appointments was divided up into 4 groups <1 week 1-2 weeks, 2-4 weeks 
and ‘don’t know’ category to allow for those whose appointments were made on their 
behalf by others. 
The results show that the waiting time for appointments was extremely short at less than 1 
week for almost 44.6% (146) of patients while only 14.1%(46) were waiting from 2 to 4 
weeks for an appointment. 
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5.4.4 Payment for prescriptions 
 
Graph 5.42 Numbers reporting having to pay for prescriptions 
 
 
Table 5.26 Number of patients paying for prescriptions 
Numbers having to pay 
for prescriptions 
Number % 
Yes 101 33.0 
No 130 42.5 
Nothing prescribed 75 24.5 
Total 306 100.0 
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Graph 5.43 If paying for prescriptions influenced participation in the treatment 
programme 
 
 
Table 5.27 Whether payment influenced treatment 
Did payment influence 
treatment 
Frequency % 
Yes 21 7 
No 76 25 
Not applicable 205 68 
Total 302 100.0 
 
When asked whether having to pay for prescriptions influenced their participation in the 
smoking cessation treatment programme, of those that responded, over 25% (76) said it did 
not, whereas only 7% (21) reported that it did. 
 
132 
 
5.4.5 Willingness to return to the service. 
 
Graph 5.44 Patients willingness to return to the service 
 
 
 
Over 94% (283) of the patients reported that they would be happy to return to the service 
again should they require it. 
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CHAPTER 6    DISCUSSION 
 
This is the most comprehensive and first independent evaluation of the smoking cessation 
services (SCS) in Ireland. EC funded projects such as PESCE and eSCCAN have looked at 
aspects of SCS in a number of other EU countries and the UK publishes regular reports on 
its services. It is clear from these projects and the EQUIPP report that there is no agreed 
‘best’ approach but there are lessons to be learned from studying the different approaches.  
I will discuss the relevant aspects from the Census Questionnaire, Treatment database and 
Patient satisfaction questionnaire separately.  
 
6.1  Census questionnaire 
6.1.1 Cessation specialists 
The Irish services are most like England and Northern Ireland but are much less well 
developed or funded. 
It was established from the census that the majority of cessation specialists were nurses 
(71.2%) similar to Northern Ireland and England but very different from many EU 
countries such as Germany where psychiatrists and psychologists are the main cessation 
specialists, or Spain Greece and Denmark where respiratory physicians are most often 
associated with treatment of tobacco dependence. France and Belgium have special 
‘tobaccologists’ who come from a variety of healthcare specialities (EQUIPP, 2011). 
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6.1.2 Training of specialist smoking cessation service providers 
 
All the specialists had smoking cessation training and the majority (58%) had had training 
in the previous 2 years. It is clear from the survey that the SPs are very conscious of the 
need and importance of continuous further training and also their willingness to participate 
where 62% identified further training as a priority. 
 There is no agreed standard of training required or accreditation demanded for the 
practicing as a smoking cessation specialist in Ireland. None of the SPs had degree level 
qualification in SC. At present there is no formal accreditation in many EU countries but 
the ENSP is trying to get consensus across the EU.  France, Belgium and the Netherlands 
have a registration process. 
 
6.1.3 Service aspects 
 
A noticeable aspect of the activities of the SPs was that very few of them were full-time SC 
practitioners with 43% giving less than 10 hrs. per week to the activity. Again this is not 
unusual in Europe but is not the norm in the UK. Most services were located in hospital 
facilities and most patients came from hospital services.  42.9% of the services were 
available to all population groups but some services limited their availability to their own 
hospital populations (in patient/outpatient and staff) 7.9 %. 
Before this study there was no national database for collection of smoking cessation 
statistics. Information and statistics on SCS was collected, mostly manually, by individual 
practitioners and reported for administrative purposes to a health board manager. What we 
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found was that the data collected was not always adequate for monitoring the service but 
also that no systematic use was made of the data collected to assess the service. Also much 
of the data collected was not analysed or used for any discernible purpose. For example, 
data on pregnancy status (32.8%), age (39.1%), gender (40.6%), number of previous quit 
attempts (53.1%), smoking history (57.8%), Fagerstrom score (37.5%) and patient status 
(25%) were collected by SPs and but no further attention or use of the data was uncovered.  
Asking SPs to collect data and not to use it, or give the SPs feedback on their service, can 
only be seen as a poor incentive for them to continue to collect, or indeed expand on the 
data collected.  
The adequacy of the resource allocated to smoking cessation is difficult to assess but using 
NICE guidelines where it is recommend that services should be available to treat some 5% 
of smokers per year; this is probably not being met in Ireland.  It is also obvious that the 
distribution of services throughout the country is uneven even when allowance is made for 
distribution of smokers.  
The difficulty of providing SC services in sparsely populated areas, as in most specialised 
healthcare services, is also evident. 
The structure of the service offered also varied greatly. This was particularly noticeable in 
scheduling of services where there was a complete lack of uniformity in the periodicity of 
follow up of patients. Only the North Western region which represents 9.5% of service 
providers have a standardised follow-up regime consisting of a weekly review for the first 4 
weeks, fortnightly up to 3 months and then  monthly for up to 1 year. This is more than 
recommended by NICE but contrasts with other Irish services where it was found that  
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currently only 47.6% of respondents follow up patients 4 weeks post their quit date 40.0% 
of whom report using CO monitoring to validate quit status often or always. 
NICE guidelines suggest: 
 SC services should aim to treat at least 5.0% of the estimated population of people who 
smoke each year. 
 That intensive support should be offered to smokers who would like to quit in weekly 
sessions for at least the first 4 weeks following a quit attempt. 
 SC services should aim for a 35% 4-week success rate validated by CO monitoring, with 
success defined as not having smoked in the third and fourth weeks following the quit date.  
This survey showed that almost a third of smoking cessation service providers did not have 
access to computers. This highlights the need for improvement in this area in both training 
of data capturing as well as financial input in developing services and implementing proper 
and uniform data collection systems throughout the country. 
 
6.2 Treatment database 
6.2.1 Quit rates. 
 
While this study was not undertaken to study the outcomes of the services in terms of 
success rate in quitting, it is clear from the data collected that the results at one and three 
months are in line with some international outcomes but lower than NHS in UK (NICE, 
2008). However more comprehensive studies of longer duration would be needed to 
confirm these findings.  
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6.2.2  Gender differences in quit rates  
 
Gender results showed that across all age groups a higher number of men were successful 
in quitting smoking than women, and the older age groups were more likely to be 
successful at quitting than their younger counterparts.  This is also in line with international 
experience. A study in 2003 found that women appear to have higher behavioural and 
lower nicotine dependence than men; therefore both nicotine and behavioural treatment 
should be tailored to women to increase their chances of abstinence (Bohadana et al., 
2003). 
 
6.2.3 Pregnancy: 
 
Pregnant women (n=118) were compared with non-pregnant women.  The quit rates of 
pregnant women at 4 weeks was 16.5% compared with 35.2% of non-pregnant women.  
The findings within pregnant women were surprising in that the quit rates achieved by them 
were disappointing.  The expectation was that their motivation to quit would be high.   
At 3 months the quit rate of pregnant women remained at 16.5% whereas their non-
pregnant counterparts quit rates fell. It could perhaps be deduced from this that if a 
pregnant woman is successful at stopping she is more likely to stay quit longer. This would 
need further research in that the stage of pregnancy is not collected in this data set and so it 
could be that they only remained quit while pregnant.  Nevertheless, is poses interesting 
questions and could indicate further worthwhile rationale in targeting women while 
pregnant, with a view to bringing down the overall smoking prevalence in women.   It 
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would also be interesting to see whether this would last beyond the term of their pregnancy. 
Pregnant women in the UK tend to be dependant smokers often with limited resources (Lee 
et al., 2006) which could be a reason for their disappointing quit rates if this was also 
shown to be true in Ireland.  Counselling from a smoking cessation specialist together with 
written support materials is effective in aiding the smoking cessation of pregnant women.  
Studies show that specialist support enables about one in 15 to stop smoking for the 
remainder of the pregnancy who would not otherwise have done so (West et al., 2000).  
The poor results may result from a paucity of services in Ireland for this population group. 
 
6.2.4 CO validation of quit status: 
 
The quit status of patients was validated by CO monitor reading done at 4 weeks on 188 
patients, which means that 427 patients who reported being quit at 4 weeks did not have 
their quit status validated. The number of cessation officers who reported CO validation in 
the census was 40%. The number of services using CO validation in the database was 20 
out of 39, which represents over 50% of those who participated.  Perhaps being involved in 
completing a database on a national level will increase reporting and therefore give rise to 
more valid and realistic results. 
 
6.4.5 Setting of quit date: 
 
The importance of setting a quit date is underlined by the fact that the quit rates amongst 
this specific group at 4 weeks was 61% and 35% at 3 months whereas overall quit rates 
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were 37% and 22% respectively.  Planning commitments and setting of a quit date has been 
shown to play an important role in smoking cessation.  Successful quit attempts have been 
shown to be markedly higher amongst those with a set quit date. (Balmford et al., 2010). 
 
6.4.7 Patient status 
 
This was broken into several categories, such as out-patients, in-patients, staff members, 
community care etc., and it was a statistically associated with quit rates at 4 weeks but not 
at 3 months.  The result was highest for staff members and this could perhaps be explained 
by motivation from working within the health sector and proximity to the service.  
 
6.4.8 Referral source 
 
This was not shown to be a statistically significant predictor of quit rates.  There were 
notably few referrals from the national Quitline or practice nurses to specialist cessation 
services.  This should be encouraged as the chances of quitting are approximately doubled 
with group therapy compared to being given self-help materials without face-to face 
instruction and support (EQUIPP, 2011). 
 
6.4.9 Number of previous quit attempts 
 
The higher the number of previous quit attempts reported by patients was shown to be a 
predictor of quit rates at 4 weeks but not so at 3 months in line with recent international 
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literature (Jardin and Carpenter, 2012).  Therefore when dealing with these patients’ greater 
efforts should be made to prevent relapse, perhaps by longer and more frequent follow up.   
 
6.4.10 Type of treatments 
 
The data showed that patients who received counselling plus a combination of NRT were 
the most successful group, however those that received both counselling and Champix were 
more likely to be successful at 3 months, although the numbers in this particular group were 
very small and further data needs to be collected in this area. The least successful group 
were those who received counselling alone. The results with regard to types of treatment 
received, on quit rates was not statistically significant, probably because of sample size but 
shows a trend towards more support and pharmacotherapy being associated with higher quit 
rates.  International results show that current pharmacological treatments are effective, and 
estimates are that the abstinence rate at 6 months among adults randomly assigned placebo 
was about 16% versus 19 to 26% across most pharmacotherapies, in contrast use of 
varenicline and combination NRT were associated with rates of 33% and 37% respectively 
(Fiore et al NEJM Sept 2011). 
There are at present no published set of smoking cessation guidelines in Ireland.  The 
National Tobacco Control Framework sets out the strategic direction for Tobacco Control 
for the next 5yrs from 2011.  An annual implementation plan will be developed, best 
practice guidelines for the management of tobacco in mental health settings have been 
developed but these are not smoking cessation guidelines (EQUIPP).   The HSE has 
developed a national standardised model for delivering training in Brief Intervention skills 
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for Smoking Cessation.  This training programme is guided by the HSE Tobacco Control 
Framework Document 2010 and incorporates the WHO recommendations of the MPOWER 
model for tobacco control. The implementation of this programme is vital for the success of 
an expansion of cessation services both because it is known that brief intervention works in 
getting people to stop smoking but also health care staff trained in brief intervention are 
also more likely to refer to more successful comprehensive treatment services. 
 
6.5 Patient satisfaction 
 
This is the first study in Ireland to provide baseline information on patients’ satisfaction on 
the currently available smoking cessation services in the four HSE areas in Ireland.  
Overwhelmingly more than 80% of patients were satisfied with the current service 
including training of staff, time and location of service and a similar number would also 
recommend these services to friends and family. This is a great tribute to the dedication and 
professionalism of the individual practitioners who provide the smoking cessation service. 
 
Having data like this from across the country will enable us to better design and target 
services suitable for different population groups.  More such surveys are needed to help 
with better design and delivery of the much needed service. It is important that the 
cessation service needs in Ireland are properly addressed, as a cost-effective comprehensive 
tobacco dependence treatment program can accelerate further declines in smoking rates 
(Currie et al., 2012). 
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CHAPTER 7  STUDY LIMITATIONS AND CONCLUSIONS 
 
7.1  Limitations 
7.1.1 Census questionnaire:  
 
This is a novel questionnaire, purpose built and therefore may not capture all important data 
but was piloted internally and among a sample of the target population of service providers. 
The lack of access to computers of some of the respondents was surprising and added to 
delay and incompleteness. 
 
7.1.2 Treatment database 
 
Only 49 service providers out of a total of 63 identified in the initial database of service 
providers agreed to pilot the treatment database.  Others were not in a position to participate 
in the project and of the 49 that agreed 39 datasets were suitable for analysis. 
Data was collected only over a 3 month period and so there were are no seasonal aspects of 
cessation rates been shown.  
Although exhaled CO monitoring was recommended the majority of smokers self-reported 
their smoking status and this gives rise to uncertainty about the validity of quit rates. 
More than 95% of the population studied was Caucasian in origin and therefore ethnicity as 
a contributor to disparities in smoking cessation cannot be applied. 
Reporting of Number of Cigarettes smoked was not always accurate, in that some cessation 
providers recorded 0 as their patients had quit that day, or within a week or so of attending 
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the service and so when analysing the level of smoking as a predictor of quitting this may 
have caused anomalies.  In future, clearer guidelines should be given to service providers 
on completing the Fagerstrom score and number of cigarettes smoked, so that the patients’ 
average numbers of cigarettes smoked when they were smoking is what should be recorded.  
While the number of cigarettes smoked was found to be a statistically significant predictor 
at 3 months, its significance may be even greater if recorded correctly and not under-
reported by service providers as was the case in this project. As well as a predictor of quit 
rates it could also help as a determinant of the treatment offered to the patients. 
 
7.1.3 Patient satisfaction survey:  
 
The number of patients who returned completed survey questionnaires was relatively small 
at 342 out of 1490 patients who were entered into the treatment programme, during the 3 
month pilot of the treatment database. 
This may be because of time constraints of the service providers, who may not have 
stressed its importance, their lack of administrative support, as well as the lack of 
motivation of patients to complete and return the forms.  Although it was explained in great 
length the anonymity of patients and the fact that completed forms would not be returned to 
their service provider they still may have had doubts or reservations about expressing their 
opinions to colleagues of their careers. Nevertheless the insight gained is worthwhile. 
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7.2 Conclusions 
 
The conclusions of this study are as follows: 
 
7.2.1 Database of cessation service providers 
 
No up to date comprehensive database of service providers and their contact details for 
circulation to health professionals to aid referrals existed. 
 
7.2.2 Census of smoking cessation services 
 
Only 1 smoking cessation service clinic was identified in a psychiatric setting. 
No standardised procedure for follow up of patients is being practiced. 
71% of Cessation SPs were from nursing background. 
Poor data collection, almost 1/3rd (32%) of SPs do not have access to a computer. 
Poor use is being made of the data collected. 
No standardised training is being given to cessation service providers, 61% identified 
further training as a priority. 
Patients who attended the services are very happy with them and 94% said that they would 
be willing to return. 
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7.2.3 Smoking cessation treatment database 
 
This study has demonstrated that quit rates achieved by the present services are 37% at 4 
weeks and 22.4% at 3 months. However amongst pregnant women the quit rates were low 
at 16%. It demonstrated consistently poor outcomes in known vulnerable subgroups of 
smokers such as youth, hard core smokers, pregnant women and those from lower SE 
groups. It also showed that referrals from sources outside of the cessation services and 
hospitals were low, as is the case in the UK, where GPs are the main referral source but still 
their referrals are low in number (McRobbie et al., 2008).  
Men had a higher quit rate than women in this study, in keeping with the results of a meta-
analysis of NHS cessation services in the UK in 2010 (Bauld et al., 2010).  
 
7.3.4  Patient satisfaction  
 
Having received and analysed responses from 342 patients who used the services, although 
a small number, it gives us better insight into their needs, likes and dislikes. It helps us to 
dispel ideas that perhaps patients would not be prepared to pay for their prescriptions in 
order to part take in a tobacco dependence treatment programme.  It also demonstrated 
quite clearly, that the time of day preferred by patients was mornings, weekdays and not 
weekends or afternoons.  After looking at the 33% who did have to pay for prescriptions 
they overwhelmingly (78.1%) reported that it did not interfere with their participation in the 
treatment programme.  
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Overall therefore, this study shows that there are Smoking Cessation Services available 
throughout the country, that all service providers have basic training and that there is 
widespread patient satisfaction with the services on offer. The results at 3 months are 
satisfactory but below expectations in the UK (NICE, 2008).  It also shows the need for 
monitoring and recording of smoking cessation activity, in order to properly evaluate fully 
its effectiveness and provide the evidence base to improve and further develop treatment 
programmes of this sinister disease. 
In order to address health inequalities smoking cessation services need to be available to all 
members of society both in rural and urban areas.  Particular attention should be given to 
maternity and psychiatric treatment centres and areas with high levels of low socio-
economic classes.  This study also shows the lack of uniformity in treatment services, 
training of SPs and monitoring of the service outcomes and highlights the need for 
significant changes. 
Although there is no agreed standard of care in Europe it is clear that the training of 
practitioners, the availability of services, the monitoring of activity and outcomes leaves 
much to be desired.  
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CHAPTER 8  RECOMMENDATIONS 
 
Based on the conclusions from this study the following recommendations emerge: 
 
8.1 Training 
 
1. That the training of smoking cessation practitioners be formalised with a requirement to 
achieve at least diploma level and higher level training at degree level needed for 
advancement.  
2. That an accreditation system is introduced and continuous professional development be 
formalised and regulated.   
3. Training for health professionals is needed to encourage them to refer smokers to 
specialist clinics. 
 
8.2 Services 
 
1. The elements of a standardised service should be agreed between relevant stakeholders 
including service providers, managers, smokers and the funding agency. 
2. That guidelines for best practice are developed and introduced and an electronic 
database be established at national level with routine monitoring of activity and 
outcomes. 
3. There should be more frequent interaction with representatives of identified groups with 
high prevalence or special problems such as mental health groups, unemployed, 
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maternity services, poverty groups and youth organisations.  Services should be 
specifically targeted towards these vulnerable groups and those in lower SE categories 
who have limited resources and access to services. 
4. That a standardised service be available to all smokers presenting for treatment at any 
cessation clinic in the country. 
5. That there be increased availability and access to web based cessation interventions. 
 
8.3 Monitoring/Surveillance 
 
1. That an up to date database of available services be maintained. 
2. That the database of services be publicised to facilitate access and referrals. 
3. That data collected be analysed and reported on, to provide the evidence base to help 
improve outcomes for the smokers wishing to quit in Ireland. 
4. That regular assessment of treatment outcomes be carried out and compared to 
international standards with recommendations for improvement where necessary. 
5. There is need to monitor the outcomes in both quit line and web based interventions. 
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Appendix 1 
Census Questionnaire 
 
 
 
 
 
 
 
     
 
RIFTFS, Irish HPH Network and IPHI 
Smoking Cessation Services in Ireland 
Questionnaire 
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This questionnaire should be completed by the person responsible for day-to-
day management and/or running of the smoking cessation service.  
Questions will cover the following areas: 
 Qualifications of staff providing the program 
 Service structure 
 Participants attending the program 
 Location of the service 
 Patient record systems  
 
All information collected in this questionnaire is for the 
purpose of data compilation and will be treated in a 
confidential manner and used only for its intended purpose. 
Audit - Smoking Cessation Services  
Smoking Cessation Service Staff Characteristics 
1. Are you        
a) A smoking cessation service provider?    
b) A smoking cessation service manager?    
2. If you are a SCS manager, please list the providers’ names in your region: 
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3. Please select your job title from the list below: 
   Smoking Cessation Officer    Tobacco Manager 
  Health Promotion Officer    Other (please specify): …………………… 
4. How long have you been in your current job? (please select one) 
   Less than 6 months    6 to 24 months 
  25 to 36 months    37 to 48 months    More than 48 months 
5. Please select your professional background: 
   Nursing   Health Promotion    Other (please specify): ………………… 
6. Have you attended specific training on smoking cessation?       Yes    No 
7. If yes, please indicate the type and duration of training below: 
Brief Intervention training 
1 day    2 days    4 days    6 days    more than 6 days    
Who offered this training? ……………………………………………………………… 
Intensive Smoking Cessation training 
1 day    2 days    4 days    6 days    more than 6 days    
Who offered this training? ……………………………………………………………… 
Train the trainers training 
1 day    2 days    4 days    6 days    more than 6 days    
Who offered this training? ……………………………………………………………… 
8. Date of most recent training attended: ………………………………………………… 
9. Do you have any specific smoking cessation training needs?      Yes    No 
10. If yes, please describe below: 
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If you are a Smoking Cessation Service Manager, you are finished completing this 
questionnaire. Please ensure that the service providers in your region complete this 
questionnaire in its entirety. Thank you for your assistance. 
If you are a Smoking Cessation Service Provider, please continue.  
 
Smoking Cessation Service (SCS) Structure 
11. To whom is the SCS available? (Please tick all that apply)  
  In-Patients    Out-Patients    Staff     Community 
  All of the above 
12. From which of the following do you receive referrals: (Please tick all that apply) 
  Primary care staff (GPs, practice nurses) 
  Pharmacists     Dental Services 
  Public health nurses    Hospital midwives 
  Hospital consultants    Self-referral 
  Other (please describe): …………………………………………………………… 
13. Which of the following smoking cessation services do you provide? (Please tick all that 
apply) 
  For:  Patients  Staff Community 
 Individual advice / counselling        
 Group advice / counselling        
 Telephone advice / counselling        
 Info on Nicotine Replacement Therapy         
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 Info on Zyban        
 Info on Champix        
Other (please specify below)       
14. If you deliver individual advice or counselling,  
 How long do individual sessions usually last? ……….  Minutes 
 On what basis do you usually provide individual advice or counselling? 
   Monthly   Fortnightly     Weekly    Twice per week  
  Once only    Other (please specify) …………..… 
15. If you deliver group advice or counseling,  
 How long do group sessions usually last?  ………. Minutes 
 How many sessions normally constitute  complete course of treatment? ……….. 
 Over what period are these sessions provided?  ……….Weeks  
16. If you deliver telephone advice or counseling, 
 How long do telephone sessions usually last? ………. Minutes 
 On what basis do you usually provide telephone advice or counseling? 
   Monthly    Fortnightly     Weekly 
  Twice per week     Once only    Other (please specify)…………. 
17. Do you follow up on patients once they have received smoking cessation support?  
  No, none of the patients receive follow up (skip to question 19) 
  Yes, all patients receive follow up 
  Yes, but only some patients receive follow up (please describe which Patients receive 
follow up in the space below) 
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18. At what period do you follow up once patients have received smoking cessation 
support? (Please tick all that apply) 
  2 weeks    1 month    3 months    6 months    1 year  
  Other (please specify) ……………………………………………………………. 
19. Do you verify self-reported successful quit attempts by CO test? 
    Never    Rarely     Sometimes    Often     Always 
20. How many patients attended your smoking cessation service in 2006? ………….. 
21. Please indicate the number of patients attending your service during each of the 
following periods:  
 Jan – Mar Apr – Jun Jul – Sep Oct - Dec  
1 – 50          
51 – 100         
101 – 150         
151 – 200         
201 – 250          
251 – 300         
> 300         
Exact number .......... ……… ………. ……….  
(if available)  
23. How many hours per week was the smoking cessation service provided in 2006?…… 
24. How many weeks per year was this smoking cessation service provided in 2006?…… 
25. Was the smoking cessation service interrupted at any time during 2006?  
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     Yes       No    
26. If yes, why and for how long was this service interrupted?........................................... 
…………………………………………………………………………………………….. 
27. Please tick any of the following groups that you specifically target with your smoking 
cessation services: 
  Homeless      People who are housebound 
  Pregnant women     Ethnic minorities 
  People with disabilities   Young people 
  People with smoking related illnesses   Economically disadvantaged 
  Hospital in-patients    People with mental illness 
  Gay and lesbian community   Others (please specify) ……………………… 
28. Please use the box below to tell us specifically how your smoking cessation service is 
targeting the groups selected above: (max 200 words). 
 
 
 
29. To which geographical areas do you provide smoking cessation services? (please tick 
all that apply) 
  Dublin     Longford     Wicklow    Offaly   
  Wexford    Westmeath      Carlow     Laois 
  Kildare    Waterford      Meath     Kerry 
  Louth    Tipperary      Monaghan     Galway 
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  Cavan     Roscommon     Kilkenny     Limerick 
  Cork     Sligo      Clare    Mayo  
  Leitrim     Donegal 
31. Please indicate all the venues used to provide your SCS and how much time is spent 
providing services in each venue per week.  Time spent/week  
  GP surgeries __________ mins  
  Other primary care centre __________ mins 
  Maternity hospital  __________ mins  
  General hospital __________ mins  
  Psychiatric hospital __________ mins  
  Pharmacies __________ mins  
  Community centres __________ mins  
  Health centres __________ mins  
  Care of the elderly setting __________ mins  
  Other  __________ mins  
(please specify) …………………………………………………………… 
Smoking Cessation Service Information Systems 
32. Is the system you use to keep patient records for the smoking cessation service users: 
  Computer based       Paper based     
  Do not currently keep patient records     Other  (Please specify)  
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33. Please tick all the fields recorded in your patient record system: 
  Name        Address  
  Gender        Age  
  Referral source      Pregnancy 
  Smoking related illnesses        Other medical conditions 
  Smoking history (length of time smoking)    Number of previous quit attempts 
  Cessation aids previously used    Cessation aids currently being used 
  Smoking frequency      Stage of behaviour change 
  Print Resources provided     Medical card status 
  Type of intervention provided    Outcome at end of program 
  Follow up and status at 1 month    Follow up and status at 3 months 
  Follow up and status at 6 months    Others (please specify) …………… 
34. If you have a separate system to collect data for analysis, is this system: 
  Computer based    MS excel   MS access   Other …………..………..  
  Paper based    Don’t currently have a system to collect data for analysis 
  Other  (Please specify)…………………………………………… 
35. Please tick all fields recorded in this system: 
  Patient demographics (name, address, gender, age etc) 
  Referral source    Pregnancy 
  Smoking related illnesses   Other medical conditions 
  Smoking history (length of time smoking)    Number of previous quit attempts 
  Cessation aids previously used    Cessation aids currently used 
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  Smoking frequency       Stage of behaviour change 
  Print Resources provided     Medical card status 
  Type of intervention provided     Outcome at end of program 
  Follow up and status at 1 month    Follow up and status at 3 months 
  Follow up and status at 6 months     Others (please specify) ………… 
Please use the box below to add any comments that you feel are relevant to this study: (max 
200 word). 
 
 
 
 
 
 
On behalf of RIFTFS, the Irish HPH Network, and the IPHI 
Thank you for taking the time to complete this questionnaire. 
Please return complete questionnaires by (DATE) to: 
RIFTFS 
The Digital Depot 
Thomas Street 
Dublin 8 
skeogan@tri.ie 
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Appendix 2 
Extract from treatment database 
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Appendix 3 
Guidance notes on the data collection instrument/ treatment database. 
This data set captures the essential information needed for the monitoring of smoking 
cessation services for this TFRI/HPH/IPHI/HSE study on services in Ireland. Full, accurate 
and timely completion of the data set in respect of each patient is a firm condition of 
participation in this study. 
 
Patient’s name, address, and telephone number will not be collected as part of this study. 
These details should be kept as part of service records in each region/centre. 
 
Please note that all fields in the data collection tool must be completed as a blank field 
will be analysed as missing data rather than 0 or a Negative answer  
e.g. Field: “Number of roll up cigarettes” should read 0 if they do not smoke them. 
 
PATIENT CONSENT 
Verbal consent should always be requested from patients for the use of data collected for 
monitoring purposes. Permission should be sought for contacts made with patients at follow 
up points such as 4 weeks, 3 months, etc.  For the duration of this study, patients should be 
informed that if they set a quit date, they will be reviewed at 4 weeks, and that CO 
monitoring will form part of this review/follow-up, unless they object to having a CO test, 
or if the follow-up is undertaken via a telephone call.  Patients should be informed that if 
they are still quit at 4 weeks, they will be offered a review at 3 months, which will also 
include CO monitoring if they are still quit. 
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Should a patient request that they would like no follow-up contacts, local records will need 
to be clearly noted so that the patient is not contacted at 4 weeks or 3 months. 
 
I.D. CODES/NUMBERS. 
 Local Patient Identifier is the very first column and can be used to store a local 
patient number or a name, in order to match a patient’s details with those records kept 
locally. This column does not have to be used and details from this column will not be part 
of the data analysed. This column will need to be deleted before the study data are sent to 
TFRI for analysis.   
Service Providers and patients will be allocated ID codes for this study.   
 Service Provider ID codes will be unique to each individual provider, and will be 
allocated on a geographical basis, thus enabling the ‘mapping’ of services.   
 Patient ID numbers will be numeric codes, starting with 01, and hence may differ 
from ID numbers/codes that are used locally.  
 
TREATMENT DATE 
This is also referred to as Date of Assessment/Date of Registration/ Date first seen, 
depending on the cessation service centre. It is the date on which a patient first meets the 
service provider. If the cessation support is provided by telephone, it would be the date on 
which the first support phone call takes place between patient and adviser. 
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DEMOGRAPHIC DATA 
Date of Birth   To be denoted as DD/MM/YYYY 
Gender   Male/Female 
Ethnic Groups    
Western Eur   Eastern Eur 
Black African   Black Caribbean 
Black Other   Irish Traveller 
Roman Gypsy   Oriental 
Middle Eastern   Indian Subcontinent 
Other 
Occupation  (Based on CSO Social Class Categorisation) 
A detailed listing of the occupations that fall under each category are provided separately. 
However, here is a quick summary of some occupations under each heading: 
1 Professional workers.   E.g. doctors, pharmacists, architects, dentists, engineers (civil/ 
electronic/software/mining/mechanical), lecturers in third level education, judges, solicitors, 
clergy, psychologists, farm owners/managers (200+ acres). 
2 Managerial and Technical. E.g. Managers of banks, hotels, shops, pubs; marketing 
managers; allied health professionals; nurses/ midwives; primary and secondary level teachers; 
farm managers/owners (100-199 acres); senior police/prison officers.  
3 Non- manual.  E.g.  Police officers & soldiers (sergeant and below); administrative officers 
and assistants in civil service and local government; hairdressers/barbers /beauticians; educational 
assistants; prof. athletes and sports officials; fire service officers; security guards; cashiers and 
bank clerks, telephone operators/salespersons, auctioneers, secretaries, personal assistants, 
receptionists; farm manager/owners (50-99 acres). 
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4 Skilled manual. e.g.  Builders, bricklayers, painters/decorators; electricians; plumbers; 
welders; motor mechanics; bakers, butchers, fishmongers, chefs, cooks; Bus/taxi drivers, 
conductors and inspectors; farm manager/owner (30-49 acres). 
5 Semi skilled. e.g. Tilers, roofers, glaziers; horticultural trades; waiters, bar staff; prison 
service officers; assemblers and line workers; packers, bottlers; seafarers; fishing and related 
workers; forestry and related workers; postal workers; porters; care assistants and attendants; 
cleaners; farm manager/owner (0-29 acres).  
6 Unskilled. E.g. farm workers; window cleaners; car park attendants. 
7 All others gainfully employed and unknown.  
PLEASE NOTE: 
 For those who are retired, their previous occupation should be used. 
 For those who are not working, e.g. a student or person working at home caring for 
children or other relations, the occupation of the main income earner in the household 
should be used. 
 For anyone who is unemployed, use their previous occupation. 
Pregnant   Yes/No 
TOBACCO CONSUMPTION AND DEPENDENCE 
- Daily consumption of cigarettes is to be recorded as the number of cigarettes per 
day. 
- If a patient smokes roll-up cigarettes, record the number of this type of cigarette 
smoked per day in the next column.  
- If a patient uses snuff or snus, please record it as ‘Y’ for ‘Yes’ in this column. 
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-  Fagerstrom Score used to measure dependence level, with 3 options as answers. 
FAGERSTROM SCORE – Questions Answers Points 
How soon after you wake do you smoke your first cigarette? Within 5 minutes 3 
  6 - 30 minutes 2 
Do you find it difficult to refrain from smoking in places where it is 
forbidden? Yes 1 
  No 0 
Which cigarette would you most hate to give up? The first of the day 1 
  All others 0 
How many cigarettes per day do you smoke? 10 or less 0 
  11 to 20 1 
  21 to 30 2 
  31 or more 3 
Do you smoke more frequently during the first hours after waking  Yes 1 
than during the rest of the day? No 0 
Do you smoke if you are so ill that you are in bed most of the day? Yes 1 
  No 0 
Score:  
0-3 Low Addiction  
4-5 Medium Addiction  
6-10 High Addiction  
 
NUMBER OF OTHERS WHO SMOKE IN THE HOUSEHOLD 
Whether a smoker lives with other people who smoke no doubt influences their efforts to 
quit. For this reason we have decided to record the number of other smokers in the 
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household. If a smoker lives with no other smokers, insert ‘0’ in this column. If the patient 
lives with one or more smokers, please insert the number of other smokers here. 
PAST HISTORY RE QUITTING. 
Has patient used this service before?  Has the patient used your cessation 
service in the past? Please answer Yes/No. 
Previous quit attempts-   This is the total number of previous quit 
attempts. Please choose one of the options listed as a response.  
Method used on last quit attempt-   Please record the type of support that the 
patient used in their most recent quit attempt.  
Options listed include: 
-Cessation programme (i.e. any cessation service/support programme) 
-Cessation programme (CP) plus nicotine replacement therapy (NRT) 
-CP plus Zyban 
-CP plus Champix 
-NRT only (i.e. without behavioural support programme) 
-Self motivation (i.e. cold turkey) 
-Zyban only 
-Champix only 
-Quit line – support from National Smokers helpline 
-Alternative therapies (acupuncture, hypnotherapy, laser therapy etc) 
-Self-help materials (e.g. booklet they may have picked up in a pharmacy/health centre)  
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CURRENT QUIT ATTEMPT 
Referred by lists a number of referral sources.  Referral source would not provide enough 
information on the type of patient, e.g. it would not highlight that a patient was a HSE staff 
member, or it would not show us which patients were in-patients. 
Patient Status allows this type of patient to be recorded. The options are: 
 Inpatient 
 Outpatient 
 Day Patient 
 Public/Community – members of the public or local community. This may also    
include members of a workplace who have enrolled in a support programme. 
 Staff members 
 Mental Health – patients who have mental health problems. Although we have included a 
referral source of ‘Mental Health services’, it is acknowledged that a number of such 
patients would actually self-refer and so their condition would not be recorded under 
referral source. Hence, as they are a priority group for cessation support it was deemed 
appropriate to have a category in this field by which this could be recorded. 
Primary Reason for Quitting 
9 reasons are listed in this field. Please record the patient’s main reason for quitting on the 
current quit attempt. 
GMS 
There are 2 types of medical card in existence in Ireland.  The original ‘Medical Card’ and 
the ‘GP Only Card’. In contrast to those with a GP Only Card, people with a Medical Card 
are entitled to free prescriptions. This would include prescriptions for pharmaceutical aids 
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that are used to treat tobacco dependence (i.e. NRT, Zyban and Champix). Data on Medical 
Card status is required in order to find out if the patient is entitled to such prescriptions. If a 
patient has a GP Only Card, then the response under the GMS heading should be 
‘No’. 
Main Type of Support Provided  
This refers to the main type of support provided on the patient’s current quit attempt.  The 
three main types of support are one-to-one, group and telephone but we have also 
differentiated between settings such as hospital and community. Hence the options to 
choose from are: 
-Hospital One-to-one    -Hospital Group 
-Community One-to-one     -Community Group 
-Telephone     -Online 
-Other 
NUMBER OF CONTACTS 
No. of Interventions less than 15 minutes long – this is the total no. of interventions that 
took place with the patient, during the study period, that lasted 15 minutes or less. These 
interventions can be face-to-face with a patient, or support delivered over the phone; 
No. of Interventions longer than 15 minutes - this is the total no. of interventions that 
took place with the patient, during the study period, that lasted more than 15 minutes. These 
interventions can be face-to-face with a patient, or where a patient has attended group 
support, or support delivered over the phone; 
Administration Contacts - this includes all the following type of contacts with patients: 
-Phone calls re appointments, or calls re follow-up monitoring 
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-Text messages re appointments or follow-up 
-Emails sent 
-Letters posted 
The number of occasions that attempts were made to contact a patient can be documented 
as part of this figure. 
PLEASE NOTE:  
FOR THOSE PATIENTS WHO DO NOT SET A QUIT DATE: 
- The number of interventions and number of admin. contacts with them should still 
be recorded. This then completes their data set as all other columns following 
Administration Contacts relate to Quit Dates and follow-up reviews. 
- The Service Satisfaction Questionnaire should be given to all patients regardless of 
whether they set a quit date or not. A copy of the Questionnaire, covering letter and 
stamped addressed envelope should be given to each patient on their last visit, or their 
last review.  
- In relation to hospital patients who are seen once or twice during their hospital stay, 
and who do not set a quit date or plan to return to you for an appointment, they 
should be given the Satisfaction Questionnaire before they leave the hospital or it can 
be posted out to them within a few days of their discharge.  
- A Satisfaction Questionnaire, cover letter and envelope should be posted out to all 
patients who do not receive them in person. 
- Be sure to affix the ID code label provided to the questionnaire before giving it to the 
patient. This ID code should match that entered into the data tool.  
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QUIT DATE 
Quit Date is the actual date on which the patient quits and should be denoted as 
DD/MM/YYYY.  Patients who set repeated “quit dates” should only be included in the 
monitoring once during the period of this study, with the outcome of the latest 
attempt.  
In the section below on Monitoring, we have detailed the Russell Standard from the 
UK, which has been adopted as guidance for monitoring. It specifies times during 
which follow-up reviews should take place. To save you time, we have programmed 
the data tool to automatically generate dates indicating the start and end of the 4 week 
and 3 month follow up periods according to the Russell Standard once a quit date has 
been entered.  
The two columns next to the Quit Date are entitled ‘Start of 4 week follow-up period’ and 
‘End of 4 week follow-up period’.  You will see that there are already dates in these 
columns (e.g. 25/01/1900 and 04/02/1900). Please ignore these but do not delete them, as 
they will automatically change to a date in 2008 once you enter a quit date. 
Once a quit date has been entered in the relevant column for a patient, two new dates will 
appear showing you the time period during which you must carry out the 4 week review or 
follow-up. For example, if a patient quits on Jan 1st, and you enter 01/01/2008 as their quit 
date, the dates that will automatically appear in the next 2 columns are 26/01/2008 and 
05/02/2008. This means that you can plan to review the patient anytime between Jan. 26th 
and Feb. 5th. 
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The data tool has also been programmed to show you their 3 month follow-up time period. 
We acknowledge that it is only those patients still quit at 4 weeks that are to be followed up 
at 3 months, but the data tool will give you these dates whether you need them or not. 
For example, when you enter a quit date for a patient quits on 01/01/2008, you will see that 
the dates that appear in the column for 3 month follow-up are 17/03/2008 and 14/04/2008, 
i.e. if the patient is still quit at 4 weeks, you then review them again anytime between 
March 17th and April 14th. 
Method used  
This aims to gather information on the use of any pharmaceutical aids on the current quit 
attempt.  All patients who set a quit date and receive the relevant aid(s) should be included. 
Clearly the expectation is that the vast majority will use the aid as directed, but this means, 
for example, that a patient who begins a course of Zyban but discontinues it (perhaps due to 
side effects) should be included. 
‘Cessation Programme and Combination therapy’ refers to patients who are being treated 
with nicotine replacement therapy in addition to either Zyban or Champix.  
FOLLOW-UP MONITORING 
(A)  4 Week Follow-Up 
Those patients who set a quit date must be followed up 4 weeks after the quit date, unless 
the patient requested that no follow-up contact be made.  If this is the case, this request can 
be documented at this follow-up point (‘Patient requested No Follow-up’ is included as a 
possible response on the database). 
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The person who provided the initial intervention should, wherever possible, carry out the 4-
week follow-up. 
Contacting patients for the 4 week follow-up 
The Russell Standard (UK) has been adopted as guidance for reviews/follow-ups. Using 
this as guidance for the 4 week review, the following applies: 
For patients who have given permission to have a review or be contacted for follow-up, the 
total time within which the 4 week review/follow-up must be completed is between 3 days 
before and 7 days after 4 weeks post the quit date. Up to 3 attempts can be made to reach 
the patient; any patient not reached after 3 attempts should be denoted as ‘Could not 
Contact’. Patients should either be seen preferably in person or contacted by telephone for 
follow-up. 
If telephone contact is not feasible for any reason a letter should be sent. Any patient not 
replying to the letter should be counted as ‘Could not Contact’.  
Completing the 4 week follow-up 
Definition of “Quit at 4 weeks” 
According to the Russell Standard, a patient is counted as a ‘self-reported 4 week quitter’ if 
they have been assessed (face to face, by postal questionnaire or by telephone) 4 weeks 
after their quit date (minus 3 days or plus 7 days) and declares that he/she has not smoked a 
single puff on a cigarette in the past 2 weeks. 
Codes available at the 4 week follow-up include: 
‘Y’ = Yes, patient still quit 
‘N’ = No, patient has relapsed 
‘Could not Contact’ 
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‘Patient RIP’ 
‘Patient requested No Follow-up’ 
Carbon Monoxide (CO) validation 
CO validation should be attempted on all patients who have said they are quit at their 4 
week follow-up/review (i.e. all those who have a ‘Yes’ in the previous column). CO 
monitoring of patients at the 4 week follow-up stage is considered to be good practice, as it 
is motivational for patients as well as a validation of their smoking status. 
Codes available under ‘CO validation’ include: 
‘CO (CO ≤6ppm)’ – if a patient has undergone CO validation of their quit status, and their 
CO reading is 6ppm or less, they are deemed still quit and this code should be recorded 
‘Self (quit status self reported)’ – if the quit status is only self report. This may happen if 
the patient is not willing to return for a review, or if they refuse to undergo a CO test, or if 
the follow-up takes place over the phone. 
‘Fail (CO ≥7ppm)’ - if a patient has undergone CO validation of their quit status, and their 
CO reading is over 7ppm, they are deemed to be not quit and this code should be recorded. 
Service providers will need to ensure the regular calibration and maintenance of CO 
monitors, in accordance with manufacturers’ instructions, in order to provide accurate and 
consistent CO monitoring and validation. 
Patients who have relapsed 
It is for cessation advisers to determine whether to encourage a patient who has failed to 
quit, but wishes to try again, to set a further quit date immediately. Patients who set 
repeated “quit dates” should only be included in the monitoring once during the period of 
this study, with the outcome of the latest attempt.  
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(B)  3 month follow-up 
Only patients who have successfully quit at 4 weeks should be followed up at 3 months.  
As already explained, the data tool is going to automatically show you the time period for 3 
month reviews but this should only be used as guidance for those patients who were still 
quit at 4 weeks. 
Using the Russell Standard as guidance for the 3 month review, the following applies: 
For patients who have given permission to have a review or be contacted for follow-up, the 
total time within which the 3 month review/follow-up must be completed is during the 
period 2 weeks either side of their  follow up date, i.e. there is a 4 week period during 
which patient can be contacted for follow-up; 
Procedure 
The same procedures for contacting a patient and undertaking CO validation should be 
followed as for the 4 week follow-up.  
Quit Status 
A patient is counted as a ‘self-reported 3 month quitter’ if they have been assessed (face to 
face, by postal questionnaire or by telephone) 3 months after their quit date (minus 14 days 
or plus 14 days) and declares that he/she has not smoked more than 5 cigarettes in the 
past 10 weeks. 
Codes available at the 3 month follow-up include: 
‘Y’ = Yes, patient still quit 
‘N’ = No, patient has relapsed 
‘Could not Contact’ 
‘Patient RIP’ 
183 
 
‘Patient requested No Follow-up’ 
Carbon Monoxide (CO) validation 
CO validation should be attempted on all patients who have said they are quit at their 3 
month follow-up/review (i.e. all those who have a ‘Yes’ in the previous column).  
Codes available under ‘CO validation’ include: 
‘CO (CO ≤6ppm)’  – if a patient has undergone CO validation of their quit status, and their 
CO reading is 6ppm or less, they are deemed still quit and this code should be recorded 
‘Self (quit status self reported)’ – if the quit status is only self report. This may happen if 
the patient is not willing to return for a review, or if they refuse to undergo a CO test, or if 
the follow-up takes place over the phone. 
‘Fail (CO ≥7ppm)’ – if a patient has undergone CO validation of their quit status, and their 
CO reading is over 7ppm, they are deemed to be not quit and this code should be recorded. 
OPTION TO INCLUDE A COMMENTARY/SHORT REPORT 
In the UK, cessation service coordinators are encouraged to complete and return ‘Quarterly 
Commentaries’ with their ‘returns’ from the NHS cessation services. The Commentaries 
are used to record key points arising from the monitoring (e.g. if unexpected problems have 
arisen within the service, or how the service development at the end of the quarter fits with 
the overall plans for the service etc.).   
As part of this study, we have decided that when data tools are being returned, we will 
provide an option of completing a short commentary to accompany data. Providers may 
feel it important to record a comment relating to the data collection, e.g. to explain a break 
in the service where no data was entered (if a provider was on leave for a period of time).  
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TFRI will remind providers in advance of the end of the study that they can include a short 
commentary when they submit their data tool. 
 
Any queries should be addressed to: 
Sheila Keogan 
01 4893637 
skeogan@tri.ie 
 
Laura Currie 
01 4893624 
lcurrie@tri.ie 
 
Paula Campbell 
Work: 041 6850673 (Thursday and Friday only) 
paula.campbell@maile.hse.ie (Thursday and Friday only) 
 
 
 
 
 
 
185 
 
Appendix 4 
 
Patient satisfaction questionnaire 
 
SMOKING CESSATION SERVICE SATISFACTION QUESTIONNAIRE 
 
 
  
1. If you were to attend a service to help you quit smoking, what day of the week 
would you prefer to attend? 
A. Weekends 
B. Weekdays 
2. At what time of day would you prefer to attend a smoking cessation support 
service? 
A. Mornings  
B. Afternoons 
C. Evenings 
WHAT WE’RE ASKING YOU TO DO – 
 
 Please try to answer every question as best as you can.  
 You can answer most questions by circling the relevant letter/number or by 
writing in a word or phrase. 
 Never circle more than one answer unless the instructions say ‘mark all 
that apply’. 
 Please do not consult with fellow workers, friends or relatives before 
completing the questionnaire. We want your answers based on your own 
experience.  
 Please do NOT write your name anywhere on the questionnaire. Your 
answers are strictly confidential and your service provider will not see them. 
THANK YOU VERY MUCH FOR YOUR COOPERATION. 
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3. How long did you have to wait for your first smoking cessation support appointment 
after contacting the service or being referred?  
A. Less than 1 week 
B. 1 to 2 weeks 
C. 2 – 4 weeks 
D. More than 4 weeks  
E. Don’t know 
 
4. What form of support do you feel would be most helpful in supporting your quit 
attempt? Mark all that apply.  
A. Group Support 
B. Individual Support (one on one) 
C. Telephone Support 
D. Online Support 
E. Other (Please specify)
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Please rate the extent to which you agree with each of the following statements. Circle the appropriate number on the scale from 1 to 
5 
Q No Statements Strongly 
Disagree 
Disagree Don’t 
know 
Agree Strongly 
Agree 
The location of the service was convenient for me.  1 2 3 4 5 
The time of day that the service was provided suited me. 1 2 3 4 5 
The day of week the service was provided suited me.  1 2 3 4 5 
The venue in which the service was provided was 
suitable.  
1 2 3 4 5 
The smoking cessation support provided met my 
expectations. 
1 2 3 4 5 
. I would feel confident recommending this service to 
friends and family.  
1 2 3 4 5 
. The staff that provided the support service seemed well 
trained to do so.   
1 2 3 4 5 
. The staff providing the service explained information 
clearly.  
1 2 3 4 5 
. The staff providing the service listened to and 
understood my concerns.  
1 2 3 4 5 
. Overall I am very satisfied with the support I have 
received at this service.  
1 2 3 4 5 
188 
 
Q No Statements Strongly 
Disagree 
Disagree Don’t 
know 
Agree Strongly 
Agree 
. 15 The time I had to wait between first contacting the service 
and receiving my first appointment was reasonable.  
1 2 3 4 5 
. 16 I was given all the information I required to support my quit 
attempt. 
1 2 3 4 5 
. 17 I felt free to ask my service provider questions at any time.  1 2 3 4 5 
. 18 The information I received was helpful in my attempt to quit 
smoking.  
1 2 3 4 5 
. 19 The support given to me made me feel more motivated and 
confident to make my quit attempt.  
1 2 3 4 5 
. 20 The length of support session(s) was long enough.  1 2 3 4 5 
. 21 The number of support sessions was suitable.  1 2 3 4 5 
. 22 The staff providing the service was supportive and caring.  1 2 3 4 5 
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23. Would you access this service again in the future if you needed further support to quit 
smoking? 
 
A. Yes 
B. No  
 
If you answered no, please explain why you would not access this service again.  
 
 
 
 
 
24. Please provide one way that this cessation service can improve support for smokers.  
 
 
 
 
25. If you were prescribed nicotine replacement therapy (eg patches, gum etc.) or medications 
(eg Zyban or Champix) to help you stop smoking, did you have to pay for them? 
A. Yes 
B. No 
C. I was not prescribed medications. 
 If Yes, did this limit your participation in the cessation programme? 
A. Yes  
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B. No 
 
26.  What is your gender? 
A. Male 
B. Female 
 
27. What is your date of birth: 
 
Date_____Month_______Year_______ 
 
Thank you very much for taking the time to complete this questionnaire your comments will help us 
to improve services in Ireland.  Please use the stamped addressed envelope to return the 
questionnaire. 
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